1
|
Guo L, Zhang B, Zhang W, Xie Y, Chen X, Sun X, Watt DS, Liu C, Spielmann HP, Liu X. Inhibition of Carbohydrate Metabolism Potentiated by the Therapeutic Effects of Oxidative Phosphorylation Inhibitors in Colon Cancer Cells. Cancers (Basel) 2024; 16:1399. [PMID: 38611076 PMCID: PMC11010912 DOI: 10.3390/cancers16071399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 03/29/2024] [Accepted: 03/31/2024] [Indexed: 04/14/2024] Open
Abstract
Cancer cells undergo a significant level of "metabolic reprogramming" or "remodeling" to ensure an adequate supply of ATP and "building blocks" for cell survival and to facilitate accelerated proliferation. Cancer cells preferentially use glycolysis for ATP production (the Warburg effect); however, cancer cells, including colorectal cancer (CRC) cells, also depend on oxidative phosphorylation (OXPHOS) for ATP production, a finding that suggests that both glycolysis and OXPHOS play significant roles in facilitating cancer progression and proliferation. Our prior studies identified a semisynthetic isoflavonoid, DBI-1, that served as an AMPK activator targeting mitochondrial complex I. Furthermore, DBI-1 and a glucose transporter 1 (GLUT1) inhibitor, BAY-876, synergistically inhibited CRC cell growth in vitro and in vivo. We now report a study of the structure-activity relationships (SARs) in the isoflavonoid family in which we identified a new DBI-1 analog, namely, DBI-2, with promising properties. Here, we aimed to explore the antitumor mechanisms of DBIs and to develop new combination strategies by targeting both glycolysis and OXPHOS. We identified DBI-2 as a novel AMPK activator using an AMPK phosphorylation assay as a readout. DBI-2 inhibited mitochondrial complex I in the Seahorse assays. We performed proliferation and Western blotting assays and conducted studies of apoptosis, necrosis, and autophagy to corroborate the synergistic effects of DBI-2 and BAY-876 on CRC cells in vitro. We hypothesized that restricting the carbohydrate uptake with a KD would mimic the effects of GLUT1 inhibitors, and we found that a ketogenic diet significantly enhanced the therapeutic efficacy of DBI-2 in CRC xenograft mouse models, an outcome that suggested a potentially new approach for combination cancer therapy.
Collapse
Affiliation(s)
- Lichao Guo
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, China
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Baochen Zhang
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, China
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Yanqi Xie
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Xi Chen
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, China
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Xueke Sun
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, China
| | - David S. Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - H. Peter Spielmann
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
| | - Xifu Liu
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, Shijiazhuang 050024, China
| |
Collapse
|
2
|
Zhang Z, Chen X, Zhang W, Liu J, Xie Y, Zhang S, Stromberg AJ, Watt DS, Liu X, Wang C, Liu C. Genomic screening methodology not requiring barcoding: Single nucleotide polymorphism-based, mixed-cell screening (SMICS). Genomics 2023; 115:110666. [PMID: 37315874 PMCID: PMC10551848 DOI: 10.1016/j.ygeno.2023.110666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 05/31/2023] [Accepted: 06/10/2023] [Indexed: 06/16/2023]
Abstract
Although high-throughput, cancer cell-line screening is a time-honored, important tool for anti-cancer drug development, this process involves the testing of each, individual drug in each, individual cell-line. Despite the availability of robotic liquid handling systems, this process remains a time-consuming and costly investment. The Broad Institute developed a new method called Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) to screen a mixture of barcoded, tumor cell-lines. Although this methodology significantly improved the efficiency of screening large numbers of cell-lines, the barcoding process itself was tedious that requires gene transfection and subsequent selection of stable cell-lines. In this study, we developed a new, genomic approach for screening multiple cancer cell-lines using endogenous "tags" that did not require prior barcoding: single nucleotide polymorphism-based, mixed-cell screening (SMICS). The code for SMICS is available at https://github.com/MarkeyBBSRF/SMICS.
Collapse
Affiliation(s)
- Zhuwei Zhang
- Department of Statistics, College of Arts and Sciences, University of Kentucky, Lexington, KY 40506, United States of America
| | - Xi Chen
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America; Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei 050024, People's Republic of China
| | - Wen Zhang
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, United States of America
| | - Jinpeng Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America
| | - Yanqi Xie
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, United States of America
| | - Shulin Zhang
- Department of Pathology and Laboratory Medicine, College of Medicine, University of Kentucky, Lexington, KY 40536, United States of America
| | - Arnold J Stromberg
- Department of Statistics, College of Arts and Sciences, University of Kentucky, Lexington, KY 40506, United States of America
| | - David S Watt
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, United States of America
| | - Xifu Liu
- Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei 050024, People's Republic of China.
| | - Chi Wang
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America; Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY 40506, United States of America.
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, United States of America; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, United States of America.
| |
Collapse
|
3
|
Chen X, Lv X, Gao L, Liu J, Wang W, Guo L, Frasinyuk MS, Zhang W, Watt DS, Liu C, Liu X. Chalcone Derivative CX258 Suppresses Colorectal Cancer via Inhibiting the TOP2A/Wnt/β-Catenin Signaling. Cells 2023; 12:cells12071066. [PMID: 37048139 PMCID: PMC10093515 DOI: 10.3390/cells12071066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 03/16/2023] [Accepted: 03/28/2023] [Indexed: 04/05/2023] Open
Abstract
The deregulation in the Wnt/β-catenin signaling pathway is associated with many human cancers, particularly colorectal cancer (CRC) and, therefore, represents a promising target for drug development. We have screened over 300 semisynthetic and natural compounds using a Wnt reporter assay and identified a family of novel chalcone derivatives (CXs) that inhibited Wnt signaling and CRC cell proliferation. Among them, we selected CX258 for further in vitro and in vivo study to investigate the molecular mechanisms. We found that CX258 significantly inhibited β-catenin expression and nuclear translocation, inducing cell cycle arrest at the G2/M phase in CRC cells. Additionally, CX258 reduced the expression of DNA Topoisomerase II alpha (TOP2A) in CRC cells. Moreover, knocking down TOP2A by siRNAs inhibited the Wnt/β-catenin signaling pathway, a finding suggesting that CX258 inhibited Wnt/β-catenin signaling and CRC cell proliferation at least partially by modulating TOP2A. Further studies showed that CDK1 that interacts with TOP2A was significantly reduced after TOP2A knockdown. We demonstrated that CX258 significantly inhibited DLD-1 CRC cell xenografts in SCID mice. In summary, we identified CX258 as a promising candidate for colorectal cancer treatment by targeting the TOP2A/Wnt/β-catenin signaling pathway.
Collapse
Affiliation(s)
- Xi Chen
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| | - Xiaocheng Lv
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| | - Lijie Gao
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| | - Jiawei Liu
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| | - Wei Wang
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| | - Lichao Guo
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| | - Mykhaylo S. Frasinyuk
- Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, 02094 Kyiv, Ukraine
| | - Wen Zhang
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
| | - David S. Watt
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
| | - Xifu Liu
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumor Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang 050024, China
| |
Collapse
|
4
|
Burikhanov R, Ganguly S, Ellingson S, Sviripa VM, Araujo N, Li S, Venkatraman P, Rao M, Choughule A, Brainson CF, Zhan CG, Spielmann HP, Watt DS, Govindan R, Rangnekar VM. Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition. Am J Cancer Res 2023; 13:976-991. [PMID: 37034206 PMCID: PMC10077052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 02/20/2023] [Indexed: 04/11/2023] Open
Abstract
Lung cancer is the leading cause of cancer-related deaths. Lung cancer cells develop resistance to apoptosis by suppressing the secretion of the tumor suppressor Par-4 protein (also known as PAWR) and/or down-modulating the Par-4 receptor GRP78 on the cell surface (csGRP78). We sought to identify FDA-approved drugs that elevate csGRP78 on the surface of lung cancer cells and induce Par-4 secretion from the cancer cells and/or normal cells in order to inhibit cancer growth in an autocrine or paracrine manner. In an unbiased screen, we identified crizotinib (CZT), an inhibitor of activated ALK/MET/ROS1 receptor tyrosine kinase, as an inducer of csGRP78 expression in ALK-negative, KRAS or EGFR mutant lung cancer cells. Elevation of csGRP78 in the lung cancer cells was dependent on activation of the non-receptor tyrosine kinase SRC by CZT. Inhibition of SRC activation in the cancer cells prevented csGRP78 translocation but promoted Par-4 secretion by CZT, implying that activated SRC prevented Par-4 secretion. In normal cells, CZT did not activate SRC and csGRP78 elevation but induced Par-4 secretion. Consequently, CZT induced Par-4 secretion from normal cells and elevated csGRP78 in the ALK-negative tumor cells to cause paracrine apoptosis in cancer cell cultures and growth inhibition of tumor xenografts in mice. Thus, CZT induces differential activation of SRC in normal and cancer cells to trigger the pro-apoptotic Par-4-GRP78 axis. As csGRP78 is a targetable receptor, CZT can be repurposed to elevate csGRP78 for inhibition of ALK-negative lung tumors.
Collapse
Affiliation(s)
- Ravshan Burikhanov
- Department of Radiation Medicine, College of Medicine, University of KentuckyLexington, Kentucky, USA
| | - Saptadwipa Ganguly
- Department of Toxicology and Cancer Biology, College of Medicine, University of KentuckyLexington, Kentucky, USA
| | - Sally Ellingson
- Department of Internal Medicine, College of Medicine, University of KentuckyLexington, Kentucky, USA
| | - Vitaliy M Sviripa
- Department of Pharmaceutical Sciences, College of Pharmacy, University of KentuckyLexington, Kentucky, USA
| | - Nathalia Araujo
- Department of Toxicology and Cancer Biology, College of Medicine, University of KentuckyLexington, Kentucky, USA
| | - Shunqiang Li
- Department of Medicine, Division of Oncology, Washington UniversitySt. Louis, Missouri, USA
| | - Prasanna Venkatraman
- Tata Memorial Centre-Advanced Centre for Treatment Research and Education in CancerNavi Mumbai, Maharashtra, India
| | - Mahadev Rao
- Department of Pharmacy Practice, Center for Translational Research, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher EducationManipal, Karnataka, India
| | - Anuradha Choughule
- Tata Memorial Centre-Advanced Centre for Treatment Research and Education in CancerNavi Mumbai, Maharashtra, India
| | - Christine F Brainson
- Department of Toxicology and Cancer Biology, College of Medicine, University of KentuckyLexington, Kentucky, USA
- Markey Cancer Center, University of KentuckyLexington, Kentucky, USA
| | - Chang-Guo Zhan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of KentuckyLexington, Kentucky, USA
| | - H Peter Spielmann
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of KentuckyLexington, Kentucky, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of KentuckyLexington, Kentucky, USA
| | - Ramaswamy Govindan
- Department of Medicine, Division of Oncology, Washington UniversitySt. Louis, Missouri, USA
| | - Vivek M Rangnekar
- Department of Radiation Medicine, College of Medicine, University of KentuckyLexington, Kentucky, USA
- Markey Cancer Center, University of KentuckyLexington, Kentucky, USA
| |
Collapse
|
5
|
Gedaly R, Cornea V, Turcios L, Edmisson JS, Harris DD, Watt DS, Chapelin F, Khurana A, Mei X, Liu C, Taylor I, Gonzalez-Valdivieso J, Mitchel H, Ruffing A, Chishti A, Orozco G, Zwischenberger J, Evers BM, Marti F. Anti-neoplastic sulfonamides alter the metabolic homeostasis and disrupt the suppressor activity of regulatory T cells. Sci Rep 2022; 12:19112. [PMID: 36352020 PMCID: PMC9646802 DOI: 10.1038/s41598-022-23601-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 11/02/2022] [Indexed: 11/11/2022] Open
Abstract
Regulatory T cells (Tregs) are essential to maintain self-tolerance and immune homeostasis but, as components of the tumor microenvironment (TME), are also a major barrier to effective cancer immunosurveillance and immunotherapy. FH535 and its derivative Y3 are two N-aryl-benzene-sulfonamides (NABs) that inhibit HCC cell proliferation and tumor progression. However, the impact of NABs on the immune cells in the TME is not yet known. Analyses of explanted livers from patients with hepatocellular carcinoma (HCC) showed that high levels of tumor-infiltrating Tregs were associated with poor tumor differentiation. These results lead us to investigate the immunomodulatory effects of NABs in regulatory and effector T cells. Exposure of primary human Tregs to NABs induced a rapid but temporary increase of cell expansion, a gradual disruption of suppressor activity, and concomitant bioenergetics and autophagic flux dysregulations. In contrast to Tregs, no gross effects were observed in effector T cells. Addition of Rapamycin prevented the functional decay of Tregs and restored their metabolic profile, suggesting that NAB effects require the integrity of the mTOR pathway. This study revealed the immunomodulatory properties of NABs with a preferential impact on Treg activity and provided novel insights into the anti-tumor potential of sulfonamides.
Collapse
Affiliation(s)
- Roberto Gedaly
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Division of Transplantation, Section for Quality and Biostatistics, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Alliance Research Initiative (TILT Alliance), College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Department of Surgery, Transplant Center, 740 South Limestone, K 301, Rm 312, Lexington, KY, 40536-0284, USA.
| | - Virgilius Cornea
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Lilia Turcios
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Jacob S Edmisson
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Dwight D Harris
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - David S Watt
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, USA
| | - Fanny Chapelin
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Alliance Research Initiative (TILT Alliance), College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Department of Biomedical Engineering, College of Medicine, University of Kentucky, Lexington, KY, 40506, USA
| | - Aman Khurana
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Alliance Research Initiative (TILT Alliance), College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Department of Radiology, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Xiaonan Mei
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Division of Transplantation, Section for Quality and Biostatistics, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Chunming Liu
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Isaac Taylor
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Juan Gonzalez-Valdivieso
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Hunter Mitchel
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Department of Science & Health, School of Science, Health & Mathematics, Asbury University, Wilmore, KY, 40390, USA
| | - Alexis Ruffing
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
- Department of Science & Health, School of Science, Health & Mathematics, Asbury University, Wilmore, KY, 40390, USA
| | - Asir Chishti
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Gabriel Orozco
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Joseph Zwischenberger
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - B Mark Evers
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA
| | - Francesc Marti
- Department of Surgery - Transplant Division, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Lucillle Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Alliance Research Initiative (TILT Alliance), College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
- Department of Surgery, Transplant Center, Peter P. Bosomworth Health Sciences Research Building (HSRB), Office: Room# 363 / Lab: Room# 361, 1095 Veterans Drive, Lexington, KY, 40536-0305, USA.
| |
Collapse
|
6
|
Guo L, Zhang W, Xie Y, Chen X, Olmstead EE, Lian M, Zhang B, Zaytseva YY, Evers BM, Spielmann HP, Liu X, Watt DS, Liu C. Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells. Mol Cancer Ther 2022; 21:740-750. [PMID: 35247917 PMCID: PMC9081236 DOI: 10.1158/1535-7163.mct-21-0925] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Revised: 01/18/2022] [Accepted: 02/15/2022] [Indexed: 01/28/2023]
Abstract
Cancer cells undergo significant "metabolic remodeling" to provide sufficient ATP to maintain cell survival and to promote rapid growth. In colorectal cancer cells, ATP is produced by mitochondrial oxidative phosphorylation and by substantially elevated cytoplasmic glucose fermentation (i.e., the Warburg effect). Glucose transporter 1 (GLUT1) expression is significantly increased in colorectal cancer cells, and GLUT1 inhibitors block glucose uptake and hence glycolysis crucial for cancer cell growth. In addition to ATP, these metabolic pathways also provide macromolecule building blocks and signaling molecules required for tumor growth. In this study, we identify a diaminobutoxy-substituted isoflavonoid (DBI-1) that inhibits mitochondrial complex I and deprives rapidly growing cancer cells of energy needed for growth. DBI-1 and the GLUT1 inhibitor, BAY-876, synergistically inhibit colorectal cancer cell growth in vitro and in vivo. This study suggests that an electron transport chain inhibitor (i.e., DBI-1) and a glucose transport inhibitor, (i.e., BAY-876) are potentially effective combination for colorectal cancer treatment.
Collapse
Affiliation(s)
- Lichao Guo
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536,Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, 050024, Shijiazhuang, China
| | - Wen Zhang
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Yanqi Xie
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Xi Chen
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536,Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, 050024, Shijiazhuang, China
| | - Emma E. Olmstead
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Mengqiang Lian
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, 050024, Shijiazhuang, China
| | - Baochen Zhang
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, 050024, Shijiazhuang, China
| | - Yekaterina Y. Zaytseva
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - B. Mark Evers
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - H. Peter Spielmann
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Xifu Liu
- Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory and Center for Drug Innovation and Discovery, College of Life Sciences, Hebei Normal University, 050024, Shijiazhuang, China,Correspondence to: , ,
| | - David S. Watt
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536,Correspondence to: , ,
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536,Correspondence to: , ,
| |
Collapse
|
7
|
Bi F, Jiang Z, Park W, Hartwich TMP, Ge Z, Chong KY, Yang K, Morrison MJ, Kim D, Kim J, Zhang W, Kril LM, Watt DS, Liu C, Yang-Hartwich Y. A Benzenesulfonamide-Based Mitochondrial Uncoupler Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Epithelial Ovarian Cancer. Mol Cancer Ther 2021; 20:2398-2409. [PMID: 34625503 PMCID: PMC8643344 DOI: 10.1158/1535-7163.mct-21-0396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 08/04/2021] [Accepted: 09/30/2021] [Indexed: 11/16/2022]
Abstract
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies and requires new therapeutic strategies to improve clinical outcomes. EOC metastasizes in the abdominal cavity through dissemination in the peritoneal fluid and ascites, efficiently adapt to the nutrient-deprived microenvironment, and resist current chemotherapeutic agents. Accumulating evidence suggests that mitochondrial oxidative phosphorylation is critical for the adaptation of EOC cells to this otherwise hostile microenvironment. Although chemical mitochondrial uncouplers can impair mitochondrial functions and thereby target multiple, essential pathways for cancer cell proliferation, traditional mitochondria uncouplers often cause toxicity that precludes their clinical application. In this study, we demonstrated that a mitochondrial uncoupler, specifically 2,5-dichloro-N-(4-nitronaphthalen-1-yl)benzenesulfonamide, hereinafter named Y3, was an antineoplastic agent in ovarian cancer models. Y3 treatment activated AMP-activated protein kinase and resulted in the activation of endoplasmic reticulum stress sensors as well as growth inhibition and apoptosis in ovarian cancer cells in vitro Y3 was well tolerated in vivo and effectively suppressed tumor progression in three mouse models of EOC, and Y3 also induced immunogenic cell death of cancer cells that involved the release of damage-associated molecular patterns and the activation of antitumor adaptive immune responses. These findings suggest that mitochondrial uncouplers hold promise in developing new anticancer therapies that delay tumor progression and protect patients with ovarian cancer against relapse.
Collapse
Affiliation(s)
- Fangfang Bi
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
- Sheng Jing Hospital of China Medical University, Shenyang, Liaoning, China
| | - Ziyan Jiang
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Wonmin Park
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
- Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Texas
| | - Tobias M P Hartwich
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
| | - Zhiping Ge
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
| | - Kay Y Chong
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
| | - Kevin Yang
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
| | - Madeline J Morrison
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
| | - Dongin Kim
- Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
| | - Jaeyeon Kim
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana
- Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky Health Care, Lexington, Kentucky
| | - Liliia M Kril
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky Health Care, Lexington, Kentucky
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky Health Care, Lexington, Kentucky
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky.
- Lucille Parker Markey Cancer Center, University of Kentucky Health Care, Lexington, Kentucky
| | - Yang Yang-Hartwich
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut.
- Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
| |
Collapse
|
8
|
Xie Y, Zhang W, Guo L, Kril LM, Begley KL, Sviripa VM, Chen X, Liu X, Lee EY, He D, Wang C, Gao T, Liu X, Evers BM, Watt DS, Liu C. Potent Synergistic Effect on C-Myc-Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor. Mol Cancer Ther 2021; 20:1893-1903. [PMID: 34376582 PMCID: PMC8492540 DOI: 10.1158/1535-7163.mct-20-1017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 03/24/2021] [Accepted: 07/23/2021] [Indexed: 11/16/2022]
Abstract
Developing effective treatments for colorectal cancers through combinations of small-molecule approaches and immunotherapies present intriguing possibilities for managing these otherwise intractable cancers. During a broad-based, screening effort against multiple colorectal cancer cell lines, we identified indole-substituted quinolines (ISQ), such as N7,N7 -dimethyl-3-(1-methyl-1H-indol-3-yl)quinoline-2,7-diamine (ISQ-1), as potent in vitro inhibitors of several cancer cell lines. We found that ISQ-1 inhibited Wnt signaling, a main driver in the pathway governing colorectal cancer development, and ISQ-1 also activated adenosine monophosphate kinase (AMPK), a cellular energy-homeostasis master regulator. We explored the effect of ISQs on cell metabolism. Seahorse assays measuring oxygen consumption rate (OCR) indicated that ISQ-1 inhibited complex I (i.e., NADH ubiquinone oxidoreductase) in the mitochondrial, electron transport chain (ETC). In addition, ISQ-1 treatment showed remarkable synergistic depletion of oncogenic c-Myc protein level in vitro and induced strong tumor remission in vivo when administered together with BI2536, a polo-like kinase-1 (Plk1) inhibitor. These studies point toward the potential value of dual drug therapies targeting the ETC and Plk-1 for the treatment of c-Myc-driven cancers.
Collapse
Affiliation(s)
- Yanqi Xie
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Lichao Guo
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei, People's Republic of China
| | - Liliia M Kril
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
| | - Kristin L Begley
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
| | - Vitaliy M Sviripa
- Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei, People's Republic of China
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
| | - Xi Chen
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei, People's Republic of China
| | - Xifu Liu
- Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei, People's Republic of China
| | - Eun Y Lee
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Department of Pathology & Laboratory Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky
| | - Daheng He
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Chi Wang
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Tianyan Gao
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Xiaoqi Liu
- Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky
| | - B Mark Evers
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, Kentucky
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky.
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky.
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| |
Collapse
|
9
|
Hammill JT, Sviripa VM, Kril LM, Ortiz D, Fargo CM, Kim HS, Chen Y, Rector J, Rice AL, Domagalska MA, Begley KL, Liu C, Rangnekar VM, Dujardin JC, Watt DS, Landfear SM, Guy RK. Amino-Substituted 3-Aryl- and 3-Heteroarylquinolines as Potential Antileishmanial Agents. J Med Chem 2021; 64:12152-12162. [PMID: 34355566 PMCID: PMC8404201 DOI: 10.1021/acs.jmedchem.1c00813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Indexed: 11/30/2022]
Abstract
Leishmaniasis, a disease caused by protozoa of the Leishmania species, afflicts roughly 12 million individuals worldwide. Most existing drugs for leishmaniasis are toxic, expensive, difficult to administer, and subject to drug resistance. We report a new class of antileishmanial leads, the 3-arylquinolines, that potently block proliferation of the intramacrophage amastigote form of Leishmania parasites with good selectivity relative to the host macrophages. Early lead 34 was rapidly acting and possessed good potency against L. mexicana (EC50 = 120 nM), 30-fold selectivity for the parasite relative to the macrophage (EC50 = 3.7 μM), and also blocked proliferation of Leishmania donovani parasites resistant to antimonial drugs. Finally, another early lead, 27, which exhibited reasonable in vivo tolerability, impaired disease progression during the dosing period in a murine model of cutaneous leishmaniasis. These results suggest that the arylquinolines provide a fruitful departure point for the development of new antileishmanial drugs.
Collapse
Affiliation(s)
- Jared T. Hammill
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
| | - Vitaliy M. Sviripa
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
- Center
for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0596, United States
- Lucille
Parker Markey Cancer Center, University
of Kentucky, Lexington, Kentucky 40536-0093, United States
| | - Liliia M. Kril
- Center
for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0596, United States
- Department
of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky 40536-0509, United States
| | - Diana Ortiz
- Department
of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon 97239, United States
| | - Corinne M. Fargo
- Department
of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon 97239, United States
| | - Ho Shin Kim
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
| | - Yizhe Chen
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
| | - Jonah Rector
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
| | - Amy L. Rice
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
| | - Malgorzata A. Domagalska
- Department
of Biomedical Sciences, Institute of Tropical
Medicine, Nationalestraat, 155, Antwerpen 2000, Belgium
| | - Kristin L. Begley
- Center
for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0596, United States
- Department
of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky 40536-0509, United States
| | - Chunming Liu
- Lucille
Parker Markey Cancer Center, University
of Kentucky, Lexington, Kentucky 40536-0093, United States
- Department
of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky 40536-0509, United States
| | - Vivek M. Rangnekar
- Lucille
Parker Markey Cancer Center, University
of Kentucky, Lexington, Kentucky 40536-0093, United States
- Department
of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40506-9983, United States
- Graduate
Center for Toxicology, College of Medicine, University of Kentucky, Lexington, Kentucky 40536-0305, United States
| | - Jean-Claude Dujardin
- Department
of Biomedical Sciences, Institute of Tropical
Medicine, Nationalestraat, 155, Antwerpen 2000, Belgium
| | - David S. Watt
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
- Center
for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0596, United States
- Lucille
Parker Markey Cancer Center, University
of Kentucky, Lexington, Kentucky 40536-0093, United States
- Department
of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky 40536-0509, United States
| | - Scott M. Landfear
- Department
of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon 97239, United States
| | - R. Kiplin Guy
- Department
of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509 United States
| |
Collapse
|
10
|
Thamban Chandrika N, Dennis EK, Brubaker KR, Kwiatkowski S, Watt DS, Garneau-Tsodikova S. Broad-Spectrum Antifungal Agents: Fluorinated Aryl- and Heteroaryl-Substituted Hydrazones. ChemMedChem 2021; 16:124-133. [PMID: 33063957 PMCID: PMC10898509 DOI: 10.1002/cmdc.202000626] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 09/28/2020] [Indexed: 12/25/2022]
Abstract
Fluorinated aryl- and heteroaryl-substituted monohydrazones displayed excellent broad-spectrum activity against various fungal strains, including a panel of clinically relevant Candida auris strains relative to a control antifungal agent, voriconazole (VRC). These monohydrazones displayed less hemolysis of murine red blood cells than that of VRC at the same concentrations, possessed fungicidal activity in a time-kill study, and exhibited no mammalian cell cytotoxicity. In addition, these monohydrazones prevented the formation of biofilms that otherwise block antibiotic effectiveness and did not trigger the development of resistance when exposed to C. auris AR Bank # 0390 over 15 passages.
Collapse
Affiliation(s)
- Nishad Thamban Chandrika
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Emily K Dennis
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Katelyn R Brubaker
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Stefan Kwiatkowski
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - David S Watt
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Sylvie Garneau-Tsodikova
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| |
Collapse
|
11
|
Thamban Chandrika N, Dennis EK, Brubaker KR, Kwiatkowski S, Watt DS, Garneau‐Tsodikova S. Cover Feature: Broad‐Spectrum Antifungal Agents: Fluorinated Aryl‐ and Heteroaryl‐Substituted Hydrazones (ChemMedChem 1/2021). ChemMedChem 2020. [DOI: 10.1002/cmdc.202000958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Nishad Thamban Chandrika
- Department of Pharmaceutical Sciences, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
| | - Emily K. Dennis
- Department of Pharmaceutical Sciences, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
| | - Katelyn R. Brubaker
- Department of Pharmaceutical Sciences, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
| | - Stefan Kwiatkowski
- Department of Pharmaceutical Sciences, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
| | - David S. Watt
- Center for Pharmaceutical Research and Innovation, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
- Department of Molecular and Cellular Biochemistry, College of Medicine University of Kentucky Lexington KY, 40536-0509 USA
| | - Sylvie Garneau‐Tsodikova
- Department of Pharmaceutical Sciences, College of Pharmacy University of Kentucky Lexington KY, 40536-0596 USA
| |
Collapse
|
12
|
Zhang W, Sviripa VM, Xie Y, Yu T, Haney MG, Blackburn JS, Adeniran CA, Zhan CG, Watt DS, Liu C. Epigenetic Regulation of Wnt Signaling by Carboxamide-Substituted Benzhydryl Amines that Function as Histone Demethylase Inhibitors. iScience 2020; 23:101795. [PMID: 33305174 PMCID: PMC7718485 DOI: 10.1016/j.isci.2020.101795] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 09/24/2020] [Accepted: 11/09/2020] [Indexed: 01/01/2023] Open
Abstract
Aberrant activation of Wnt signaling triggered by mutations in either Adenomatous Polyposis Coli (APC) or CTNNB1 (β-catenin) is a hallmark of colorectal cancers (CRC). As part of a program to develop epigenetic regulators for cancer therapy, we developed carboxamide-substituted benzhydryl amines (CBAs) bearing either aryl or heteroaryl groups that selectively targeted histone lysine demethylases (KDMs) and functioned as inhibitors of the Wnt pathway. A biotinylated variant of N-((5-chloro-8-hydroxyquinolin-7-yl) (4-(diethylamino)phenyl)-methyl)butyramide (CBA-1) identified KDM3A as a binding partner. KDM3A is a Jumonji (JmjC) domain-containing demethylase that is significantly upregulated in CRC. KDM3A regulates the demethylation of histone H3's lysine 9 (H3K9Me2), a repressive marker for transcription. Inhibiting KDM3 increased H3K9Me2 levels, repressed Wnt target genes, and curtailed in vitro CRC cell proliferation. CBA-1 also exhibited in vivo inhibition of Wnt signaling in a zebrafish model without displaying in vivo toxicity. A class of carboxamide-substituted benzhydryl amine (CBA) Wnt inhibitors A biological active, biotinylated CBA to identify KDM3A as a direct target CBA-1 interacted with the Mn2+ ion in the JmjC domains of KDM3A/3B CBA-1 inhibited Wnt signaling in colon cancer cells and in zebrafish models
Collapse
Affiliation(s)
- Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
| | - Vitaliy M. Sviripa
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| | - Yanqi Xie
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
| | - Tianxin Yu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
| | - Meghan G. Haney
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
| | - Jessica S. Blackburn
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
| | - Charles A. Adeniran
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
- Molecular Modeling and Pharmaceutical Center, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| | - Chang-Guo Zhan
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
- Molecular Modeling and Pharmaceutical Center, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| | - David S. Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
- Corresponding author
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
- Corresponding author
| |
Collapse
|
13
|
Sviripa VM, Fiandalo MV, Begley KL, Wyrebek P, Kril LM, Balia AG, Parkin SR, Subramanian V, Chen X, Williams AH, Zhan CG, Liu C, Mohler JL, Watt DS. Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins. NEW J CHEM 2020; 44:13415-13429. [PMID: 33795928 DOI: 10.1039/d0nj02664f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Androgen-deprivation therapy (ADT) is only a palliative measure, and prostate cancer invariably recurs in a lethal, castration-resistant form (CRPC). Prostate cancer resists ADT by metabolizing weak, adrenal androgens to growth-promoting 5α-dihydrotestosterone (DHT), the preferred ligand for the androgen receptor (AR). Developing small-molecule inhibitors for the final steps in androgen metabolic pathways that utilize 17-oxidoreductases required probes that possess fluorescent groups at C-3 and intact, naturally occurring functionality at C-17. Application of the Pictet-Spengler condensation to substituted 4-(2-aminoethyl)coumarins and 5α-androstane-3-ones furnished spirocyclic, fluorescent androgens at the desired C-3 position. Condensations required the presence of activating C-7 amino or N,N-dialkylamino groups in the 4-(2-aminoethyl)coumarin component of these condensation reactions. Successful Pictet-Spengler condensation, for example, of DHT with 9-(2-aminoethyl)-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinolin-11-one led to a spirocyclic androgen, (3R,5S,10S,13S,17S)-17-hydroxy-10,13-dimethyl-1,2,2',3',4,5,6,7,8,8',9,9',10,11,12,12',13,13',14,15,16,17-docosahydro-7'H,11'H-spiro-[cyclopenta[a]phenanthrene-3,4'-pyrido[3,2,1-ij]pyrido[4',3':4,5]pyrano[2,3-f]quinolin]-5'(1'H)-one. Computational modeling supported the surrogacy of the C-3 fluorescent DHT analog as a tool to study 17-oxidoreductases for intracrine, androgen metabolism.
Collapse
Affiliation(s)
- Vitaliy M Sviripa
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093 USA
| | - Michael V Fiandalo
- Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263 USA
| | - Kristin L Begley
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Przemyslaw Wyrebek
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Liliia M Kril
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Andrii G Balia
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Sean R Parkin
- Department of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY 40506 USA
| | | | - Xi Chen
- College of Chemistry and Material Science, South Central University for Nationalities, Wuhan 430074, People's Republic of China
| | - Alexander H Williams
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA
| | - Chang-Guo Zhan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - James L Mohler
- Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263 USA.,Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263 USA
| | - David S Watt
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| |
Collapse
|
14
|
Tang B, Frasinyuk MS, Chikwana VM, Mahalingan KK, Morgan CA, Segvich DM, Bondarenko SP, Mrug GP, Wyrebek P, Watt DS, DePaoli-Roach AA, Roach PJ, Hurley TD. Discovery and Development of Small-Molecule Inhibitors of Glycogen Synthase. J Med Chem 2020; 63:3538-3551. [PMID: 32134266 DOI: 10.1021/acs.jmedchem.9b01851] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The overaccumulation of glycogen appears as a hallmark in various glycogen storage diseases (GSDs), including Pompe, Cori, Andersen, and Lafora disease. Accumulating evidence suggests that suppression of glycogen accumulation represents a potential therapeutic approach for treating these GSDs. Using a fluorescence polarization assay designed to screen for inhibitors of the key glycogen synthetic enzyme, glycogen synthase (GS), we identified a substituted imidazole, (rac)-2-methoxy-4-(1-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-phenyl-1H-imidazol-5-yl)phenol (H23), as a first-in-class inhibitor for yeast GS 2 (yGsy2p). Data from X-ray crystallography at 2.85 Å, as well as kinetic data, revealed that H23 bound within the uridine diphosphate glucose binding pocket of yGsy2p. The high conservation of residues between human and yeast GS in direct contact with H23 informed the development of around 500 H23 analogs. These analogs produced a structure-activity relationship profile that led to the identification of a substituted pyrazole, 4-(4-(4-hydroxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyrogallol, with a 300-fold improved potency against human GS. These substituted pyrazoles possess a promising scaffold for drug development efforts targeting GS activity in GSDs associated with excess glycogen accumulation.
Collapse
Affiliation(s)
- Buyun Tang
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | - Mykhaylo S Frasinyuk
- V. P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv 02094, Ukraine.,National University of Food Technologies, Kyiv 01601, Ukraine
| | - Vimbai M Chikwana
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | - Krishna K Mahalingan
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | - Cynthia A Morgan
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | - Dyann M Segvich
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | | | - Galyna P Mrug
- V. P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv 02094, Ukraine.,National University of Food Technologies, Kyiv 01601, Ukraine
| | - Przemyslaw Wyrebek
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington 40506, Kentucky, United States.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington 40536, Kentucky, United States
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington 40506, Kentucky, United States.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington 40536, Kentucky, United States.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington 40536, Kentucky, United States
| | - Anna A DePaoli-Roach
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | - Peter J Roach
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| | - Thomas D Hurley
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202, Indiana, United States
| |
Collapse
|
15
|
Howard KC, Dennis EK, Watt DS, Garneau-Tsodikova S. A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise. Chem Soc Rev 2020; 49:2426-2480. [PMID: 32140691 DOI: 10.1039/c9cs00556k] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The emergence of new fungal pathogens makes the development of new antifungal drugs a medical imperative that in recent years motivates the talents of numerous investigators across the world. Understanding not only the structural families of these drugs but also their biological targets provides a rational means for evaluating the merits and selectivity of new agents for fungal pathogens and normal cells. An equally important aspect of modern antifungal drug development takes a balanced look at the problems of drug potency and drug resistance. The future development of new antifungal agents will rest with those who employ synthetic and semisynthetic methodology as well as natural product isolation to tackle these problems and with those who possess a clear understanding of fungal cell architecture and drug resistance mechanisms. This review endeavors to provide an introduction to a growing and increasingly important literature, including coverage of the new developments in medicinal chemistry since 2015, and also endeavors to spark the curiosity of investigators who might enter this fascinatingly complex fungal landscape.
Collapse
Affiliation(s)
- Kaitlind C Howard
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | | | | | | |
Collapse
|
16
|
Zhang W, Sviripa VM, Kril LM, Yu T, Xie Y, Hubbard WB, Sullivan PG, Chen X, Zhan CG, Yang-Hartwich Y, Evers BM, Spear BT, Gedaly R, Watt DS, Liu C. An Underlying Mechanism of Dual Wnt Inhibition and AMPK Activation: Mitochondrial Uncouplers Masquerading as Wnt Inhibitors. J Med Chem 2019; 62:11348-11358. [PMID: 31774672 PMCID: PMC7560992 DOI: 10.1021/acs.jmedchem.9b01685] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The importance of upregulated Wnt signaling in colorectal cancers led to efforts to develop inhibitors that target β-catenin in this pathway. We now report that several "Wnt inhibitors" that allegedly target β-catenin actually function as mitochondrial proton uncouplers that independently activate AMPK and concomitantly inhibit Wnt signaling. As expected for a process in which mitochondrial uncoupling diminishes ATP production, a mitochondrial proton uncoupler, FCCP, and a glucose metabolic inhibitor, 2-DG, activated AMPK and inhibited Wnt signaling. Also consistent with these findings, a well-known "Wnt inhibitor", FH535, functioned as a proton uncoupler, and in support of this finding, the N-methylated analog, 2,5-dichloro-N-methyl-N-(2-methyl-4-nitrophenyl)benzenesulfonamide (FH535-M), was inactive as an uncoupler and Wnt inhibitor. Apart from suggesting an opportunity to develop dual Wnt inhibitors and AMPK activators, these findings provide a cautionary tale that claims for Wnt inhibition alone require scrutiny as possible mitochondrial proton uncouplers or inhibitors of the electron transport chain.
Collapse
Affiliation(s)
- Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| | - Vitaliy M. Sviripa
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Liliia M. Kril
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Tianxin Yu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| | - Yanqi Xie
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| | - W. Brad Hubbard
- Department of Neuroscience, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Patrick G. Sullivan
- Department of Neuroscience, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Xi Chen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Chang-Guo Zhan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Yang Yang-Hartwich
- Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine LSOG 209, 375 Congress Avenue, New Haven CT 06510
| | - B. Mark Evers
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Brett T. Spear
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
- Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY 40536
| | - Roberto Gedaly
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536
- Transplant Center, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - David S. Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
17
|
Park W, Hartwich TMP, Chong KY, Liu C, Watt DS, Kim D, Yang-Hartwich Y. Abstract NT-116: TARGETING UNFOLDED PROTEIN RESPONSE FOR OVARIAN CANCER THERAPY. Clin Cancer Res 2019. [DOI: 10.1158/1557-3265.ovcasymp18-nt-116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Standard paclitaxel-platinum-based chemotherapies often lead to relapses and chemoresistant diseases. New therapeutic strategies are urgently needed for improving the clinical outcomes of ovarian caner patients. Our goal is to identify dysfunctional cellular pathways that are critical for tumor progression and drug resistance and to design novel therapeutic interventions that affect these altered cellular functions.
The dysregulation of unfolded protein response (UPR) pathway is often found in cancer cells and contributes to cancer cell survival and their resistance to stress caused by chemotherapies, hypoxia, and nutrition deprivation. The objective of our research is to develop new therapeutic agents to target UPR in ovarian cancer cells in order to overcome chemoresistance.
Sulfonamides (SFs) have been used to synthesize antibacterial drugs. We have recently discovered a family of new SFs with anticancer activity. Based on preliminary study, we hypothesize that these new SFs induce apoptosis in ovarian cancer cells through targeting UPR.
Using one of the SFs, namely SF-Y3, we compared its effects on epithelial ovarian cancer (EOC) cell lines and immortalized normal fallopian tube (FT) cell lines by performing luminescent CellTiter assay. Phospho-S6 ribosomal protein (P-S6) staining and Annexin V-FITC/PI staining assays were performed to evaluate the effects of SF-Y3 on cell health. Human transcriptome array (HTA) was used to identify the gene expression changes in SF-Y3-treated EOC cells, which results were confirmed by quantitative real-time PCR (qPCR). Western blot and XBP1 RNA splicing PCR were performed to assess the activation of proteins in UPR pathway. Using 4u8c, an inhibitor of the ER transmembrane protein IRE1, we determined whether inhibiting UPR could rescue cancer cells from the SF-Y3-induced apoptosis. Co-immunoprecipitation (co-PI) was used to determine the effects of SF-Y3 on the ER membrane protein-protein interaction. Moreover, we encapsulated SF-Y3 with nanoparticle to improve its bioavailability for evaluating the in vivo efficacy in EOC mouse model as a single treatment and in combination with platinum-based chemotherapy.
The cell viability data demonstrated that SF-Y3 significantly reduced the viability of EOC cells expressing high levels of Bip1, a key chaperone protein in the endoplasmic. SF-Y3 was less effective in EOC cells with low levels of Bip1 and has no effects on normal FT cells. P-S6 and Annexin V staining assays demonstrated that SF-Y3 inhibited EOC cell proliferation and induced apoptosis. HTA and qPCR data showed that the UPR genes were unregulated by SF-Y3. Western blot and XBP1 RNA splicing PCR results indicated that SF-Y3 activated proteins in the UPR pathway, including ATF6, PERK, eIF2α, XBP1, and CHOP. SF-Y3 interrupted the interaction between Bip1 and three ER membrane-associated sensors, supporting that Bip1 is a possible target of SF-Y3. UPR inhibitor 4u8c partially rescued the apoptosis induced by SF-Y3. These data support that SF-Y3 has anticancer activity in EOC models possibly through inhibiting Bip1 and inducing UPR-induced apoptosis. Further investigation of how SFs interact with Bip1 and UPR pathway in vitro and in vivo may lead to new approaches to overcome drug resistance and a significant therapeutic advance for EOC.
Citation Format: Wonmin Park, Tobias MP. Hartwich, Kay Y. Chong, Chunming Liu, David S. Watt, Dongin Kim, Yang Yang-Hartwich. TARGETING UNFOLDED PROTEIN RESPONSE FOR OVARIAN CANCER THERAPY [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr NT-116.
Collapse
Affiliation(s)
- Wonmin Park
- 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT,
- 2Department of Pharmaceutical Sciences, Texas A&M University,
| | - Tobias MP. Hartwich
- 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT,
| | - Kay Y. Chong
- 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT,
| | | | | | - Dongin Kim
- 2Department of Pharmaceutical Sciences, Texas A&M University,
| | - Yang Yang-Hartwich
- 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT,
| |
Collapse
|
18
|
Sinner HF, Johnson J, Rychahou PG, Watt DS, Zaytseva YY, Liu C, Evers BM. Novel chemotherapeutic agent, FND-4b, activates AMPK and inhibits colorectal cancer cell proliferation. PLoS One 2019; 14:e0224253. [PMID: 31648230 PMCID: PMC6812860 DOI: 10.1371/journal.pone.0224253] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 10/10/2019] [Indexed: 12/19/2022] Open
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer deaths in the US with the majority of deaths due to metastatic disease. Current chemotherapeutic regimens involve highly toxic agents, which limits their utility; therefore, more effective and less toxic agents are required to see a reduction in CRC mortality. Novel fluorinated N,N’-diarylureas (FND) were developed and characterized by our group as potent activators of adenosine monophosphate-activated kinase (AMPK) that inhibit cell cycle progression. The purpose of this study was to determine the effect of a lead FND compound, FND-4b, either alone or combined with PI-103 (a dual PI3K/mTOR inhibitor) or SN-38 (active metabolite of irinotecan) on cell cycle arrest and apoptosis of CRC cell lines (both commercially-available and novel lines established from our patient population). Treatment with FND-4b for 24h resulted in a marked induction of phosphorylated AMPK expression and a concomitant reduction in markers of cell proliferation, such as cyclin D1, in all CRC cell lines. Apoptosis was also notably increased in CRC cells treated with FND-4b. Regardless of the genetic profile of the CRC cells, FND-4b treatment alone resulted in decreased cell proliferation. Moreover, the combination of FND-4b with PI-103 resulted in increased cell death in all cell lines, while the combination of FND-4b with SN-38 resulted in increased cell death in select cell lines. Our findings identify FND-4b, which activates AMPK at micromolar concentrations, as a novel and effective inhibitor of CRC growth either alone or in combination with PI-103 and SN-38.
Collapse
Affiliation(s)
- Heather F. Sinner
- Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America
- Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| | - Jeremy Johnson
- Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America
| | - Piotr G. Rychahou
- Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America
- Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| | - David S. Watt
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, United States of America
- Center for Molecular Medicine, Organic Synthesis Core, University of Kentucky, Lexington, Kentucky, United States of America
| | - Yekaterina Y. Zaytseva
- Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America
| | - Chunming Liu
- Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, United States of America
| | - B. Mark Evers
- Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America
- Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- * E-mail:
| |
Collapse
|
19
|
Xie Y, Kril LM, Yu T, Zhang W, Frasinyuk MS, Bondarenko SP, Kondratyuk KM, Hausman E, Martin ZM, Wyrebek PP, Liu X, Deaciuc A, Dwoskin LP, Chen J, Zhu H, Zhan CG, Sviripa VM, Blackburn J, Watt DS, Liu C. Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude mice and myc-induced T-ALL in zebrafish. Sci Rep 2019; 9:6439. [PMID: 31015569 PMCID: PMC6478746 DOI: 10.1038/s41598-019-42917-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 12/17/2018] [Indexed: 02/07/2023] Open
Abstract
Structure-activity relationships (SAR) in the aurone pharmacophore identified heterocyclic variants of the (Z)-2-benzylidene-6-hydroxybenzofuran-3(2H)-one scaffold that possessed low nanomolar in vitro potency in cell proliferation assays using various cancer cell lines, in vivo potency in prostate cancer PC-3 xenograft and zebrafish models, selectivity for the colchicine-binding site on tubulin, and absence of appreciable toxicity. Among the leading, biologically active analogs were (Z)-2-((2-((1-ethyl-5-methoxy-1H-indol-3-yl)methylene)-3-oxo-2,3-dihydrobenzofuran-6-yl)oxy)acetonitrile (5a) and (Z)-6-((2,6-dichlorobenzyl)oxy)-2-(pyridin-4-ylmethylene)benzofuran-3(2H)-one (5b) that inhibited in vitro PC-3 prostate cancer cell proliferation with IC50 values below 100 nM. A xenograft study in nude mice using 10 mg/kg of 5a had no effect on mice weight, and aurone 5a did not inhibit, as desired, the human ether-à-go-go-related (hERG) potassium channel. Cell cycle arrest data, comparisons of the inhibition of cancer cell proliferation by aurones and known antineoplastic agents, and in vitro inhibition of tubulin polymerization indicated that aurone 5a disrupted tubulin dynamics. Based on molecular docking and confirmed by liquid chromatography-electrospray ionization-tandem mass spectrometry studies, aurone 5a targets the colchicine-binding site on tubulin. In addition to solid tumors, aurones 5a and 5b strongly inhibited in vitro a panel of human leukemia cancer cell lines and the in vivo myc-induced T cell acute lymphoblastic leukemia (T-ALL) in a zebrafish model.
Collapse
Affiliation(s)
- Yanqi Xie
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Liliia M Kril
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Tianxin Yu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - Mykhaylo S Frasinyuk
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
- Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv, 02094, Ukraine
| | | | - Kostyantyn M Kondratyuk
- Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv, 02094, Ukraine
| | - Elizabeth Hausman
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Zachary M Martin
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Przemyslaw P Wyrebek
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Xifu Liu
- Center for Drug Innovation and Discovery, Hebei Normal University, Shijiazhuang, Hebei, 050024, People's Republic of China
| | - Agripina Deaciuc
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Linda P Dwoskin
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Jing Chen
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Haining Zhu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Chang-Guo Zhan
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
- Molecular Modeling and Pharmaceutical Center, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Vitaliy M Sviripa
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Jessica Blackburn
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA.
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA.
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA.
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA.
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA.
| |
Collapse
|
20
|
Johnson J, Rychahou P, Sviripa VM, Weiss HL, Liu C, Watt DS, Evers BM. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers. PLoS One 2019; 14:e0209392. [PMID: 30875375 PMCID: PMC6420029 DOI: 10.1371/journal.pone.0209392] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 03/06/2019] [Indexed: 12/13/2022] Open
Abstract
Purpose Triple negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer. AMP-activated protein kinase (AMPK) is a major energy regulator that suppresses tumor growth, and 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a novel AMPK activator that inhibits growth and induces apoptosis in colon cancer. The purpose of this project was to test the effects of FND-4b on AMPK activation, proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC. Materials and methods (i) Estrogen-receptor positive breast cancer (ER+BC; MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast cancer stem cells were treated with FND-4b for 24h. Immunoblot analysis assessed AMPK, acetyl-CoA carboxylase (ACC), ribosomal protein S6, cyclin D1, and cleaved PARP. (ii) Sulforhodamine B growth assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h. Proliferation was also assessed by counting cells after 72h of FND-4b treatment. (iii) Cell death ELISA assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h. Results (i) FND-4b increased AMPK activation with concomitant decreases in ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii) FND-4b decreased proliferation in all cells, while dose-dependent growth decreases were found in ER+BC and TNBC. (iii) Increases in apoptosis were observed in ER+BC and the MDA-MB-231 cell line with FND-4b treatment. Conclusions Our findings indicate that FND-4b decreases proliferation for a variety of breast cancers by activating AMPK and has notable effects on TNBC. The growth reductions were mediated through decreases in fatty acid synthesis (ACC), mTOR signaling (S6), and cell cycle flux (cyclin D1). ER+BC cells were more susceptible to FND-4b-induced apoptosis, but MDA-MB-231 cells still underwent apoptosis with higher dose treatment. Further development of FND compounds could result in a novel therapeutic for TNBC.
Collapse
Affiliation(s)
- Jeremy Johnson
- Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America
| | - Piotr Rychahou
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America
| | - Vitaliy M. Sviripa
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America
| | - Heidi L. Weiss
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - David S. Watt
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America
| | - B. Mark Evers
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America
- * E-mail:
| |
Collapse
|
21
|
Turcios L, Chacon E, Garcia C, Eman P, Cornea V, Jiang J, Spear B, Liu C, Watt DS, Marti F, Gedaly R. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma. PLoS One 2019; 14:e0212538. [PMID: 30794613 PMCID: PMC6386480 DOI: 10.1371/journal.pone.0212538] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2018] [Accepted: 02/05/2019] [Indexed: 12/14/2022] Open
Abstract
Autophagy targets cellular components for lysosomal-dependent degradation in which the products of degradation may be recycled for protein synthesis and utilized for energy production. Autophagy also plays a critical role in cell homeostasis and the regulation of many physiological and pathological processes and prompts this investigation of new agents to effect abnormal autophagy in hepatocellular carcinoma (HCC). 2,5-Dichloro-N-(2-methyl-4-nitrophenyl) benzenesulfonamide (FH535) is a synthetic inhibitor of the Wnt/β-catenin pathway that exhibits anti-proliferative and anti-angiogenic effects on different types of cancer cells. The combination of FH535 with sorafenib promotes a synergistic inhibition of HCC and liver cancer stem cell proliferation, mediated in part by the simultaneous disruption of mitochondrial respiration and glycolysis. We demonstrated that FH535 decreased HCC tumor progression in a mouse xenograft model. For the first time, we showed the inhibitory effect of an FH535 derivative, FH535-N, alone and in combination with sorafenib on HCC cell proliferation. Our study revealed the contributing effect of Wnt/β-catenin pathway inhibition by FH535 and its derivative (FH535-N) through disruption of the autophagic flux in HCC cells.
Collapse
Affiliation(s)
- Lilia Turcios
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| | - Eduardo Chacon
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - Catherine Garcia
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - Pedro Eman
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - Virgilius Cornea
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| | - Jieyun Jiang
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Microbiology, Immunology & Molecular Genetics, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - Brett Spear
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Microbiology, Immunology & Molecular Genetics, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
| | - David S. Watt
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America
| | - Francesc Marti
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| | - Roberto Gedaly
- Department of Surgery, Transplant Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America
| |
Collapse
|
22
|
Thamban Chandrika N, Dennis EK, Shrestha SK, Ngo HX, Green KD, Kwiatkowski S, Deaciuc AG, Dwoskin LP, Watt DS, Garneau-Tsodikova S. N,N'-diaryl-bishydrazones in a biphenyl platform: Broad spectrum antifungal agents. Eur J Med Chem 2018; 164:273-281. [PMID: 30597328 DOI: 10.1016/j.ejmech.2018.12.042] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 11/11/2018] [Accepted: 12/17/2018] [Indexed: 11/18/2022]
Abstract
N,N'-Diaryl-bishydrazones of [1,1'-biphenyl]-3,4'-dicarboxaldehyde, [1,1'-biphenyl]-4,4'-dicarboxaldehyde, and 4,4'-bisacetyl-1,1-biphenyl exhibited excellent antifungal activity against a broad spectrum of filamentous and non-filamentous fungi. These N,N'-diaryl-bishydrazones displayed no antibacterial activity in contrast to previously reported N,N'-diamidino-bishydrazones and N-amidino-N'-aryl-bishydrazones. The leading candidate, 4,4'-bis((E)-1-(2-(4-fluorophenyl)hydrazono)ethyl)-1,1'-biphenyl, displayed less hemolysis of murine red blood cells at concentrations at or below that of a control antifungal agent (voriconazole), was fungistatic in a time-kill study, and possessed no mammalian cytotoxicity and no toxicity with respect to hERG inhibition.
Collapse
Affiliation(s)
- Nishad Thamban Chandrika
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Emily K Dennis
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Sanjib K Shrestha
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Huy X Ngo
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Keith D Green
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Stefan Kwiatkowski
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Agripina Gabriela Deaciuc
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - Linda P Dwoskin
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA
| | - David S Watt
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0509, USA; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA.
| | - Sylvie Garneau-Tsodikova
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA.
| |
Collapse
|
23
|
Mrug GP, Demydchuk BA, Bondarenko SP, Sviripa VM, Wyrebek P, Mohler JL, Fiandalo MV, Liu C, Frasinyuk MS, Watt DS. A Direct Synthesis of 2‐(ω‐Carboxyalkyl)isoflavones from
ortho
‐Hydroxylated Deoxybenzoins. European J Org Chem 2018. [DOI: 10.1002/ejoc.201801171] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Galyna P. Mrug
- Institute of Bioorganic Chemistry and Petrochemistry National Academy of Science of Ukraine 02094 Kyiv Ukraine
| | - Bohdan A. Demydchuk
- Institute of Bioorganic Chemistry and Petrochemistry National Academy of Science of Ukraine 02094 Kyiv Ukraine
| | | | - Vitaliy M. Sviripa
- Center for Pharmaceutical Research and Innovation College of Pharmacy University of Kentucky 0509 Lexington KY 40536‐ USA
- Department of Pharmaceutical Sciences College of Pharmacy University of Kentucky 40536‐0509 Lexington KY USA
| | - Przemyslaw Wyrebek
- Center for Pharmaceutical Research and Innovation College of Pharmacy University of Kentucky 0509 Lexington KY 40536‐ USA
- Department of Molecular and Cellular Biochemistry College of Medicine University of Kentucky 40536‐0509 Lexington KY USA
| | - James L. Mohler
- Department of Urology Roswell Park Cancer Institute 14263 Buffalo NY USA
| | | | - Chunming Liu
- Department of Molecular and Cellular Biochemistry College of Medicine University of Kentucky 40536‐0509 Lexington KY USA
- Lucille Parker Markey Cancer Center University of Kentucky 40536‐0509 Lexington KY USA
| | - Mykhaylo S. Frasinyuk
- Institute of Bioorganic Chemistry and Petrochemistry National Academy of Science of Ukraine 02094 Kyiv Ukraine
- Center for Pharmaceutical Research and Innovation College of Pharmacy University of Kentucky 0509 Lexington KY 40536‐ USA
- Department of Molecular and Cellular Biochemistry College of Medicine University of Kentucky 40536‐0509 Lexington KY USA
| | - David S. Watt
- Center for Pharmaceutical Research and Innovation College of Pharmacy University of Kentucky 0509 Lexington KY 40536‐ USA
- Department of Molecular and Cellular Biochemistry College of Medicine University of Kentucky 40536‐0509 Lexington KY USA
- Lucille Parker Markey Cancer Center University of Kentucky 40536‐0509 Lexington KY USA
| |
Collapse
|
24
|
Cook SF, Fiandalo MV, Watt DS, Wu Y, Mohler JL, Bies RR. Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate 2018; 78:1069-1076. [PMID: 29938815 DOI: 10.1002/pros.23665] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 06/07/2018] [Indexed: 12/12/2022]
Abstract
BACKGROUND Progression of castration-recurrent/resistant prostate cancer (CRPC) relies in part on dihydrotestosterone derived from intratumoral androgen metabolism. Mathematical modeling provides a valuable tool for studies of androgen metabolism in CRPC. This modeling approach integrates existing knowledge about complex biologic systems and provides a means of interrogating the effects of various interventions. We sought to model a single reaction in the androgen biosynthesis network, namely the oxidation of androsterone (AND) to androstanedione (5α-dione) by four 3α-oxidoreductase enzymes, as an initial effort to establish the feasibility of our modeling approach. METHODS Models were constructed for two cell culture systems, a non-prostate cancer cell line (CV-1) and a prostate cancer cell line (LAPC-4), using the SimBiology app (version 5.3) in MATLAB (version 8.6). The models included components for substrate (AND), product (5α-dione), each of the four enzymes, and each of the four enzyme-substrate complexes. Each enzymatic reaction consisted of a reversible enzyme-substrate binding step and an irreversible catalysis step. Rates of change for each component were described using ordinary differential equations. RESULTS Mathematical models were developed with model parameter values derived from literature sources or from existing experimental data, which included gene expression measurements and substrate and product concentrations determined using liquid chromatography-tandem mass spectrometry. The models for both cell lines adequately described substrate and product concentrations observed after 12 h treatment with AND. CONCLUSIONS This modeling approach represents an adaptable, extensible and mechanistic framework that reflects androgen metabolism. The models can be expanded systematically to describe the complex androgen metabolic pathways important for study of novel therapies for CRPC.
Collapse
Affiliation(s)
- Sarah F Cook
- Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York
| | | | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, Kentucky
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Yue Wu
- Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
| | - James L Mohler
- Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
| | - Robert R Bies
- Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York
- Computational and Data-Enabled Science and Engineering Program, University at Buffalo, State University of New York, Buffalo, New York
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York
| |
Collapse
|
25
|
Frasinyuk MS, Zhang W, Wyrebek P, Yu T, Xu X, Sviripa VM, Bondarenko SP, Xie Y, Ngo HX, Morris AJ, Mohler JL, Fiandalo MV, Watt DS, Liu C. Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4). Org Biomol Chem 2018; 15:7623-7629. [PMID: 28868548 DOI: 10.1039/c7ob01584d] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Cytisine-linked isoflavonoids (CLIFs) inhibited PC-3 prostate and LS174T colon cancer cell proliferation by inhibiting a peroxisomal bifunctional enzyme. A pull-down assay using a biologically active, biotin-modified CLIF identified the target of these agents as the bifunctional peroxisomal enzyme, hydroxysteroid 17β-dehydrogenase-4 (HSD17B4). Additional studies with truncated versions of HSD17B4 established that CLIFs specifically bind the C-terminus of HSD17B4 and selectively inhibited the enoyl CoA hydratase but not the d-3-hydroxyacyl CoA dehydrogenase activity. HSD17B4 was overexpressed in prostate and colon cancer tissues, knocking down HSD17B4 inhibited cancer cell proliferation, suggesting that HSD17B4 is a potential biomarker and drug target and that CLIFs are potential probes or therapeutic agents for these cancers.
Collapse
Affiliation(s)
- Mykhaylo S Frasinyuk
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Sviripa VM, Kril LM, Zhang W, Xie Y, Wyrebek P, Ponomareva L, Liu X, Yuan Y, Zhan CG, Watt DS, Liu C. Phenylethynyl-substituted Heterocycles Inhibit Cyclin D1 and Induce the Expression of Cyclin-dependent Kinase Inhibitor p21 Wif1/Cip1 in Colorectal Cancer Cells. Medchemcomm 2018. [PMID: 29527286 DOI: 10.1039/c7md00393e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Fluorinated, phenylethynyl-substituted heterocycles that possessed either an N-methylamino or N,N-dimethylamino group attached to heterocycles including pyridines, indoles, 1H-indazoles, quinolines, and isoquinolines inhibited the proliferation of LS174T colon cancer cells in which the inhibition of cyclin D1 and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21Wif1/Cip1) served as a readout for antineoplastic activity at a cellular level. On a molecular level, these agents, particularly 4-((2,6-difluorophenyl)ethynyl)-N-methylisoquinolin-1-amine and 4-((2,6-difluorophenyl)ethynyl)-N,N-dimethylisoquinolin-1-amine, bound and inhibited the catalytic subunit of methionine S-adenosyltransferase-2 (MAT2A).
Collapse
Affiliation(s)
- Vitaliy M Sviripa
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596
| | - Liliia M Kril
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093
| | - Yanqi Xie
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093
| | - Przemyslaw Wyrebek
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509
| | - Larissa Ponomareva
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596
| | - Xifu Liu
- Epionc, Inc., P.O. Box 23436, Lexington, KY 40523
| | - Yaxia Yuan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky 40536-0596
| | - Chang-Guo Zhan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky 40536-0596
| | - David S Watt
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596.,Epionc, Inc., P.O. Box 23436, Lexington, KY 40523.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093
| | - Chunming Liu
- Epionc, Inc., P.O. Box 23436, Lexington, KY 40523.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093
| |
Collapse
|
27
|
Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL. Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget 2018; 9:11227-11242. [PMID: 29541409 PMCID: PMC5834294 DOI: 10.18632/oncotarget.24107] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2017] [Accepted: 11/19/2017] [Indexed: 11/25/2022] Open
Abstract
Androgen deprivation therapy (ADT) is palliative and prostate cancer (CaP) recurs as lethal castration-recurrent/resistant CaP (CRPC). One mechanism that provides CaP resistance to ADT is primary backdoor androgen metabolism, which uses up to four 3α-oxidoreductases to convert 5α-androstane-3α,17β-diol (DIOL) to dihydrotestosterone (DHT). The goal was to determine whether inhibition of 3α-oxidoreductase activity decreased conversion of DIOL to DHT. Protein sequence analysis showed that the four 3α-oxidoreductases have identical catalytic amino acid residues. Mass spectrometry data showed combined treatment using catalytically inactive 3α-oxidoreductase mutants and the 5α-reductase inhibitor, dutasteride, decreased DHT levels in CaP cells better than dutasteride alone. Combined blockade of frontdoor and backdoor pathways of DHT synthesis provides a therapeutic strategy to inhibit CRPC development and growth.
Collapse
Affiliation(s)
- Michael V. Fiandalo
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - John J. Stocking
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Elena A. Pop
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - John H. Wilton
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Krystin M. Mantione
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Yun Li
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Kristopher M. Attwood
- Department of Biostatistics and Bioinformatics Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Gissou Azabdaftari
- Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - Yue Wu
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | - David S. Watt
- Center for Pharmaceutical Research and Innovation and Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40536, USA
| | - Elizabeth M. Wilson
- Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA
| | - James L. Mohler
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| |
Collapse
|
28
|
Burikhanov R, Hebbar N, Noothi SK, Shukla N, Sledziona J, Araujo N, Kudrimoti M, Wang QJ, Watt DS, Welch DR, Maranchie J, Harada A, Rangnekar VM. Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis. Cell Rep 2017; 18:508-519. [PMID: 28076793 PMCID: PMC5264245 DOI: 10.1016/j.celrep.2016.12.051] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 05/05/2016] [Accepted: 12/15/2016] [Indexed: 12/11/2022] Open
Abstract
The induction of tumor suppressor proteins capable of cancer cell apoptosis represents an attractive option for the re-purposing of existing drugs. We report that the anti-malarial drug, chloroquine (CQ), is a robust inducer of Par-4 secretion from normal cells in mice and cancer patients in a clinical trial. CQ-inducible Par-4 secretion triggers paracrine apoptosis of cancer cells and also inhibits metastatic tumor growth. CQ induces Par-4 secretion via the classical secretory pathway that requires the activation of p53. Mechanistically, p53 directly induces Rab8b, a GTPase essential for vesicle transport of Par-4 to the plasma membrane prior to secretion. Our findings indicate that CQ induces p53- and Rab8b-dependent Par-4 secretion from normal cells for Par-4-dependent inhibition of metastatic tumor growth.
Collapse
Affiliation(s)
- Ravshan Burikhanov
- Department of Radiation Medicine, University of Kentucky, Lexington, KY 40356, USA
| | - Nikhil Hebbar
- Graduate Center for Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40356, USA
| | - Sunil K Noothi
- Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY 40356, USA
| | - Nidhi Shukla
- Graduate Center for Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40356, USA
| | - James Sledziona
- Graduate Center for Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40356, USA
| | - Nathália Araujo
- Graduate Center for Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40356, USA
| | - Meghana Kudrimoti
- Department of Radiation Medicine, University of Kentucky, Lexington, KY 40356, USA
| | - Qing Jun Wang
- Graduate Center for Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40356, USA; Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40356, USA
| | - David S Watt
- Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40356, USA; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40356, USA
| | - Danny R Welch
- Department of Cancer Biology, University of Kansas, Kansas City, KS 66160, USA
| | - Jodi Maranchie
- Department of Urology, University of Pittsburgh, Pittsburgh, PA 15232, USA
| | - Akihiro Harada
- Department of Cell Biology, Osaka University, Osaka 565-0871, Japan
| | - Vivek M Rangnekar
- Department of Radiation Medicine, University of Kentucky, Lexington, KY 40356, USA; Graduate Center for Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40356, USA; Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY 40356, USA; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40356, USA.
| |
Collapse
|
29
|
Kenlan DE, Rychahou P, Sviripa VM, Weiss HL, Liu C, Watt DS, Evers BM. Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 2017; 16:831-837. [PMID: 28258165 DOI: 10.1158/1535-7163.mct-15-0634] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Revised: 09/01/2015] [Accepted: 01/30/2017] [Indexed: 12/25/2022]
Abstract
Colorectal cancer is the second-leading cause of cancer-related mortality in the United States. More than 50% of patients with colorectal cancer will develop local recurrence or distant organ metastasis. Cancer stem cells play a major role in the survival and metastasis of cancer cells. In this study, we examined the effects of novel AMP-activated protein kinase (AMPK) activating compounds on colorectal cancer metastatic and stem cell lines as potential candidates for chemotherapy. We found that activation of AMPK by all fluorinated N,N-diarylureas (FND) compounds at micromolar levels significantly inhibited the cell-cycle progression and subsequent cellular proliferation. In addition, we demonstrated that select FNDs significantly increased apoptosis in colorectal cancer metastatic and cancer stem cells. Therefore, FNDs hold considerable promise in the treatment of metastatic colorectal cancer, through elimination of both regular cancer cells and cancer stem cells. Mol Cancer Ther; 16(5); 831-7. ©2017 AACR.
Collapse
Affiliation(s)
- Dasha E Kenlan
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Piotr Rychahou
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky.,Department of Surgery, University of Kentucky, Lexington, Kentucky
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky
| | - Heidi L Weiss
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky
| | - B Mark Evers
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky. .,Department of Surgery, University of Kentucky, Lexington, Kentucky
| |
Collapse
|
30
|
Shrestha SK, Kril LM, Green KD, Kwiatkowski S, Sviripa VM, Nickell JR, Dwoskin LP, Watt DS, Garneau-Tsodikova S. Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. Bioorg Med Chem 2016; 25:58-66. [PMID: 27769670 DOI: 10.1016/j.bmc.2016.10.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 10/06/2016] [Accepted: 10/07/2016] [Indexed: 11/18/2022]
Abstract
The emergence of multidrug-resistant bacterial and fungal strains poses a threat to human health that requires the design and synthesis of new classes of antimicrobial agents. We evaluated bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones for their antibacterial and antifungal activities against panels of Gram-positive/Gram-negative bacteria as well as fungi. We investigated their potential to develop resistance against both bacteria and fungi by a multi-step resistance-selection method, explored their potential to induce the production of reactive oxygen species, and assessed their toxicity. In summary, we found that these compounds exhibited broad-spectrum antibacterial and antifungal activities against most of the tested strains with minimum inhibitory concentration (MIC) values ranging from <0.5 to >500μM against bacteria and 1.0 to >31.3μg/mL against fungi; and in most cases, they exhibited either superior or similar antimicrobial activity compared to those of the standard drugs used in the clinic. We also observed minimal emergence of drug resistance to these newly synthesized compounds by bacteria and fungi even after 15 passages, and we found weak to moderate inhibition of the human Ether-à-go-go-related gene (hERG) channel with acceptable IC50 values ranging from 1.12 to 3.29μM. Overall, these studies show that bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones are potentially promising scaffolds for the discovery of novel antibacterial and antifungal agents.
Collapse
Affiliation(s)
- Sanjib K Shrestha
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596, USA
| | - Liliia M Kril
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596, USA; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
| | - Keith D Green
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596, USA
| | - Stefan Kwiatkowski
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| | - Justin R Nickell
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596, USA
| | - Linda P Dwoskin
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA.
| | - Sylvie Garneau-Tsodikova
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone Street, Lexington, KY 40536-0596, USA.
| |
Collapse
|
31
|
Sviripa VM, Burikhanov R, Obiero JM, Yuan Y, Nickell JR, Dwoskin LP, Zhan CG, Liu C, Tsodikov OV, Rangnekar VM, Watt DS. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. Org Biomol Chem 2016; 14:74-84. [PMID: 26548370 DOI: 10.1039/c5ob01980j] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Advanced prostate tumors usually metastasize to the lung, bone, and other vital tissues and are resistant to conventional therapy. Prostate apoptosis response-4 protein (Par-4) is a tumor suppressor that causes apoptosis in therapy-resistant prostate cancer cells by binding specifically to a receptor, Glucose-regulated protein-78 (GRP78), found only on the surface of cancer cells. 3-Arylquinolines or "arylquins" induce normal cells to release Par-4 from the intermediate filament protein, vimentin and promote Par-4 secretion that targets cancer cells in a paracrine manner. A structure-activity study identified arylquins that promote Par-4 secretion, and an evaluation of arylquin binding to the hERG potassium ion channel using a [(3)H]-dofetilide binding assay permitted the identification of structural features that separated this undesired activity from the desired Par-4 secretory activity. A binding study that relied on the natural fluorescence of arylquins and that used the purified rod domain of vimentin (residues 99-411) suggested that the mechanism behind Par-4 release involved arylquin binding to multiple sites in the rod domain.
Collapse
Affiliation(s)
- Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA. and Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| | - Ravshan Burikhanov
- Department of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, KY 40506-9983, USA. and Lucille Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY 40536-0096, USA
| | - Josiah M Obiero
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | - Yaxia Yuan
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | - Justin R Nickell
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | - Linda P Dwoskin
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | - Chang-Guo Zhan
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA and Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA. and Lucille Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY 40536-0096, USA
| | - Oleg V Tsodikov
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA.
| | - Vivek M Rangnekar
- Department of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, KY 40506-9983, USA. and Lucille Parker Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY 40536-0096, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA. and Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| |
Collapse
|
32
|
Rychahou P, Kenlan D, Sviripa VM, Watt DS, Evers BM. Abstract 1222: Fluorinated N, N-diarylureas treatment as effective strategy to target colorectal cancer stem cells. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-1222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Colorectal (CRC) cancer is the second leading cause of cancer deaths in the US; treatment of metastatic CRCs is limited due to drug resistance and eventual relapse. Cancer stem cells and PI3K mutation (i.e., pik3ca mutation) have been implicated in the relapse and lack of treatment response for many cancers including CRCs; therefore, it is critical to develop a therapeutic strategy that eliminates both the fast-growing cancer cells and the more resistant cancer stem cells. The purpose of the present study was to evaluate the anticancer activity of recently-described, novel AMPK activators, fluorinated N, N-diarylureas (FNDs), against CRC metastatic cell lines, pik3ca mutant cell lines, and CRC stem cells. METHODS. i) First, to assess AMPK activation, metastatic CRC cell lines (HT29 and KM20 cells), HCT116 pik3ca wild-type (WT) and mutant (MUT) cell lines, and CRC stem cell lines (from Celprogen) were treated with varying concentrations of 8 FNDs (4a, 4b, 4h, 4j, 4k, 4z, 4aa, 4bb). AMPK activation and activation of the upstream regulator, LKB1, was assessed by western blot. ii) Next, we determined the effect of the FNDs and, for comparison, metformin (an AMPK activator) on induction of cell cycle suppression and induction of apoptosis as assessed by cyclin D1 expression and PARP cleavage, respectively; β-actin antibody was used as a loading control. RESULTS. i) Treatment with the FNDs resulted in AMPK activation in HT29 and KM20 cells and CRC stem cells at concentrations as low as 10 μM with a peak activation at 12 h. We observed LKB1-independent AMPK kinase activation. Decreased LKB1 phosphorylation after FND treatment was dose dependent (i.e., decreased by ∼50% at 10 μM and undetectable at 50 μM). ii) All 8 FNDs (at a 25 μM dosage) completely suppressed cyclin D1 expression in HT29 and KM20 cells; a similar cyclin D1 suppression was noted with metformin at a 500x higher dosage (i.e., 10mM). Five of the 8 FNDs (4b, 4j, 4z, 4aa, 4bb) increased PARP cleavage in HT29 and KM20 cells. We used these 5 FNDs (at a dosage of 50 μM each) to treat the CRC stem cell lines; cyclin D1 suppression was noted for all 5 FNDs but strong induction of apoptosis was only identified using the 4b FND. Finally, we treated HCT116 pik3ca WT and MUT cell lines with 4b FND and found that cyclin D1 expression was completely suppressed at 40 μM and induction of apoptosis was noted at a dosage of 20 μM. CONCLUSIONS. We demonstrate cell cycle suppression and apoptosis in CRC cells and stem cells using the recently-developed FND compounds with the 4b compound as the most effective. These compounds appear to have considerable promise as a targeted cancer stem cell-specific agents and offer a potentially novel strategy for the treatment of CRC metastases.
Citation Format: Piotr Rychahou, Dasha Kenlan, Vitaliy M. Sviripa, David S. Watt, B. Mark Evers. Fluorinated N, N-diarylureas treatment as effective strategy to target colorectal cancer stem cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1222.
Collapse
Affiliation(s)
- Piotr Rychahou
- 1University of Kentucky Markey Cancer Center and Department of Surgery, Lexington, KY
| | - Dasha Kenlan
- 2University of Kentucky Markey Cancer Center, Lexington, KY
| | - Vitaliy M. Sviripa
- 3University of Kentucky Department of Molecular and Cellular Biochemistry, Lexington, KY
| | - David S. Watt
- 3University of Kentucky Department of Molecular and Cellular Biochemistry, Lexington, KY
| | - B. Mark Evers
- 1University of Kentucky Markey Cancer Center and Department of Surgery, Lexington, KY
| |
Collapse
|
33
|
Frasinyuk MS, Mrug GP, Bondarenko SP, Khilya VP, Sviripa VM, Syrotchuk OA, Zhang W, Cai X, Fiandalo MV, Mohler JL, Liu C, Watt DS. Antineoplastic Isoflavonoids Derived from Intermediate ortho-Quinone Methides Generated from Mannich Bases. ChemMedChem 2016; 11:600-11. [PMID: 26889756 DOI: 10.1002/cmdc.201600008] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Revised: 02/08/2016] [Indexed: 12/31/2022]
Abstract
The regioselective condensations of various 7-hydroxyisoflavonoids with bis(N,N-dimethylamino)methane in a Mannich reaction provided C-8 N,N-dimethylaminomethyl-substituted isoflavonoids in good yield. Similar condensations of 7-hydroxy-8-methylisoflavonoids led to the C-6-substituted analogs. Thermal eliminations of dimethylamine from these C-6 or C-8 N,N-dimethylaminomethyl-substituted isoflavonoids generated ortho-quinone methide intermediates within isoflavonoid frameworks for the first time. Despite other potential competing outcomes, these ortho-quinone methide intermediates trapped dienophiles including 2,3-dihydrofuran, 3,4-dihydro-2H-pyran, 3-(N,N-dimethylamino)-5,5-dimethyl-2-cyclohexen-1-one, 1-morpholinocyclopentene, and 1-morpholinocyclohexene to give various inverse electron-demand Diels-Alder adducts. Several adducts derived from 8-N,N-dimethylaminomethyl-substituted isoflavonoids displayed good activity in the 1-10 μm concentration range in an in vitro proliferation assay using the PC-3 prostate cancer cell line.
Collapse
Affiliation(s)
- Mykhaylo S Frasinyuk
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0596, USA. .,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0509, USA. .,Department of Chemistry of Bioactive Nitrogen-Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv, 02094, Ukraine.
| | - Galyna P Mrug
- Department of Chemistry of Bioactive Nitrogen-Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv, 02094, Ukraine
| | - Svitlana P Bondarenko
- Department of Chemistry, Taras Shevchenko Kyiv National University, Kyiv, 01601, Ukraine
| | - Volodymyr P Khilya
- Department of Chemistry, Taras Shevchenko Kyiv National University, Kyiv, 01601, Ukraine
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0596, USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0509, USA
| | - Oleksandr A Syrotchuk
- Central Laboratory for Quality Control of Medicines and Medical Products, Kyiv, 04053, Ukraine
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0596, USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - Xianfeng Cai
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0596, USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - Michael V Fiandalo
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
| | - James L Mohler
- Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0596, USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536-0596, USA. .,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0509, USA. .,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA.
| |
Collapse
|
34
|
Xu X, Watt DS, Liu C. Multifaceted roles for thymine DNA glycosylase in embryonic development and human carcinogenesis. Acta Biochim Biophys Sin (Shanghai) 2016; 48:82-9. [PMID: 26370152 DOI: 10.1093/abbs/gmv083] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2015] [Accepted: 07/12/2015] [Indexed: 01/03/2023] Open
Abstract
Thymine DNA glycosylase (TDG) is a multifunctional protein that plays important roles in DNA repair, DNA demethylation, and transcriptional regulation. These diverse functions make TDG a unique enzyme in embryonic development and carcinogenesis. This review discusses the molecular function of TDG in human cancers and the previously unrecognized value of TDG as a potential target for drug therapy.
Collapse
Affiliation(s)
- Xuehe Xu
- Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0509, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0509, USA
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0509, USA
| |
Collapse
|
35
|
Pumphrey A, Yang Z, Ye S, Powell DK, Thalman S, Watt DS, Abdel-Latif A, Unrine J, Thompson K, Fornwalt B, Ferrauto G, Vandsburger M. Advanced cardiac chemical exchange saturation transfer (cardioCEST) MRI for in vivo cell tracking and metabolic imaging. NMR Biomed 2016; 29:74-83. [PMID: 26684053 PMCID: PMC4907269 DOI: 10.1002/nbm.3451] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Revised: 10/16/2015] [Accepted: 11/03/2015] [Indexed: 05/03/2023]
Abstract
An improved pre-clinical cardiac chemical exchange saturation transfer (CEST) pulse sequence (cardioCEST) was used to selectively visualize paramagnetic CEST (paraCEST)-labeled cells following intramyocardial implantation. In addition, cardioCEST was used to examine the effect of diet-induced obesity upon myocardial creatine CEST contrast. CEST pulse sequences were designed from standard turbo-spin-echo and gradient-echo sequences, and a cardiorespiratory-gated steady-state cine gradient-echo sequence. In vitro validation studies performed in phantoms composed of 20 mM Eu-HPDO3A, 20 mM Yb-HPDO3A, or saline demonstrated similar CEST contrast by spin-echo and gradient-echo pulse sequences. Skeletal myoblast cells (C2C12) were labeled with either Eu-HPDO3A or saline using a hypotonic swelling procedure and implanted into the myocardium of C57B6/J mice. Inductively coupled plasma mass spectrometry confirmed cellular levels of Eu of 2.1 × 10(-3) ng/cell in Eu-HPDO3A-labeled cells and 2.3 × 10(-5) ng/cell in saline-labeled cells. In vivo cardioCEST imaging of labeled cells at ±15 ppm was performed 24 h after implantation and revealed significantly elevated asymmetric magnetization transfer ratio values in regions of Eu-HPDO3A-labeled cells when compared with surrounding myocardium or saline-labeled cells. We further utilized the cardioCEST pulse sequence to examine changes in myocardial creatine in response to diet-induced obesity by acquiring pairs of cardioCEST images at ±1.8 ppm. While ventricular geometry and function were unchanged between mice fed either a high-fat diet or a corresponding control low-fat diet for 14 weeks, myocardial creatine CEST contrast was significantly reduced in mice fed the high-fat diet. The selective visualization of paraCEST-labeled cells using cardioCEST imaging can enable investigation of cell fate processes in cardioregenerative medicine, or multiplex imaging of cell survival with imaging of cardiac structure and function and additional imaging of myocardial creatine.
Collapse
Affiliation(s)
- Ashley Pumphrey
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
| | - Zhengshi Yang
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
| | - Shaojing Ye
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
| | - David K. Powell
- Department of Anatomy and Neurobiology, University of Kentucky, Lexington, KY, USA
| | - Scott Thalman
- Department of Biomedical Engineering, University of Kentucky, Lexington, KY, USA
| | - David S. Watt
- Department of Molecular and Cellular Biochemistry, University of Kentucky, and Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, USA
| | - Ahmed Abdel-Latif
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
| | - Jason Unrine
- Department of Plant and Soil Sciences, University of Kentucky, Lexington, KY, USA
| | | | - Brandon Fornwalt
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
- Geisinger Health System, Danville, PA, USA
| | - Giuseppe Ferrauto
- Molecular Imaging Center, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy
| | - Moriel Vandsburger
- Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA
- Department of Biomedical Engineering, University of Kentucky, Lexington, KY, USA
- Department of Physiology, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
36
|
Frasinyuk MS, Mrug GP, Bondarenko SP, Sviripa VM, Zhang W, Cai X, Fiandalo MV, Mohler JL, Liu C, Watt DS. Application of Mannich bases to the synthesis of hydroxymethylated isoflavonoids as potential antineoplastic agents. Org Biomol Chem 2015; 13:11292-301. [PMID: 26416505 DOI: 10.1039/c5ob01828e] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The regiospecific Mannich aminomethylation of 7-hydroxyisoflavonoids using bis(N,N-dimethylamino)methane afforded C-8 substituted N,N-dimethylaminomethyl adducts, and the regioselective aminomethylation of 5-hydroxy-7-methoxyisoflavonoids afforded predominantly the C-6 substituted N,N-dimethylaminomethyl adducts. Acetylation of these C-6 or C-8 Mannich bases with potassium acetate in acetic anhydride provided access to the corresponding acetoxymethyl derivatives that were subsequently converted to hydroxymethyl- and methoxymethyl-substituted 5-hydroxy- or 7-hydroxyisoflavonoids related to naturally occurring flavonoids. The C-8 acetoxymethyl, hydroxymethyl or methoxymethyl-substituted isoflavonoids possessed promising inhibitory potency in the low micromolar range in a prostate cancer PC-3 cell proliferation assay.
Collapse
Affiliation(s)
- Mykhaylo S Frasinyuk
- Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv 02094, Ukraine
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kril LM, Vilchez V, Jiang J, Turcios L, Chen C, Sviripa VM, Zhang W, Liu C, Spear B, Watt DS, Gedaly R. N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and β-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells. Bioorg Med Chem Lett 2015; 25:3897-9. [PMID: 26243371 PMCID: PMC4540627 DOI: 10.1016/j.bmcl.2015.07.040] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2015] [Revised: 07/15/2015] [Accepted: 07/17/2015] [Indexed: 02/07/2023]
Abstract
Structure-activity relationships (SAR) in 2,5-dichloro-N-(2-methyl-4-nitrophenyl)benzenesulfonamide (FH535) were examined as part of a program to identify agents that inhibit the Wnt/β-catenin signaling pathway that is frequently upregulated in hepatocellular carcinoma (HCC). FH535 was reported as an inhibitor of both β-catenin in the Wnt signaling pathway and the peroxisome proliferator-activated receptor (PPAR). A β-catenin/T-cell factor (TCF)/Lymphoid-enhancer factor (LEF)-dependent assay (i.e., luciferase-based TOPFlash assay) as well as a [(3)H]-thymidine incorporation assay were used to explore SAR modifications of FH535. Although replacing the 2,5-dichlorophenylsulfonyl substituent in FH535 with a 2,6-dihalogenation pattern generally produced more biologically active analogs than FH535, other SAR modifications led only to FH535 analogs with comparable or slightly improved activity in these two assays. The absence of a clear SAR pattern in activity suggested a multiplicity of target effectors for N-aryl benzenesulfonamides.
Collapse
Affiliation(s)
- Liliia M Kril
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Valery Vilchez
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Jieyun Jiang
- Department of Microbiology, Immunology & Molecular Genetics, University of Kentucky, Lexington, KY 40536-0093, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| | - Lilia Turcios
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Changguo Chen
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| | - Brett Spear
- Department of Microbiology, Immunology & Molecular Genetics, University of Kentucky, Lexington, KY 40536-0093, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States.
| | - Roberto Gedaly
- Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536-0596, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States.
| |
Collapse
|
38
|
Yeo SCM, Sviripa VM, Huang M, Kril L, Watt DS, Liu C, Lin HS. Analysis of trans-2,6-difluoro-4'-(N,N-dimethylamino)stilbene (DFS) in biological samples by liquid chromatography-tandem mass spectrometry: metabolite identification and pharmacokinetics. Anal Bioanal Chem 2015; 407:7319-32. [PMID: 26229026 DOI: 10.1007/s00216-015-8893-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2015] [Revised: 06/10/2015] [Accepted: 07/01/2015] [Indexed: 02/06/2023]
Abstract
The metabolism of a promising antineoplastic agent, trans-2,6-difluoro-4'-(N,N-dimethylamino)stilbene (DFS), was studied in mouse, rat, and human liver microsomes using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with the multiple reaction monitoring-information-dependent acquisition-enhanced product ion scan (MRM-IDA-EPI) method. Ten putative metabolites were identified and the structures of four metabolites were confirmed using authentic standards. Since trans-2,6-difluoro-4'-(N-methylamino)stilbene (DMDFS, M1) was present in all species as metabolite and displayed in vitro growth inhibition superior to DFS, its pharmacokinetic profiles were examined in Sprague-Dawley rats using DFS as a comparator. A reliable LC-MS/MS multiple reaction monitoring (MRM) method was subsequently developed and validated for the simultaneous quantification of both DFS and DMDFS in rat plasma for this purpose. Upon intravenous administration (4 mg/kg), DFS had a moderate clearance (Cl = 62.7 ± 23.2 mL/min/kg), terminal elimination half-life (t 1/2 λZ = 299 ± 73 min), and mean transit time (MTT = 123 ± 14 min) with demethylation metabolism accounting for about 10 % of its total clearance. DMDFS possessed an intravenous pharmacokinetic profile similar to DFS. During oral dosing (10 mg/kg) where both DFS and DMDFS were absorbed rapidly, the oral bioavailability of DFS was approximately 2-fold greater than that of DMDFS (DFS: F = 42.1 ± 12.8 %; DMDFS: F = 18.7 ± 3.9 %). Interestingly, the DMDFS exposure after oral dosing of DFS (10 mg/kg) was comparable to that after oral administration of DMDFS (10 mg/kg) alone. As DFS displayed potent anticancer activities and excellent pharmacokinetic profiles, it appears to be a favorable candidate for further pharmaceutical development.
Collapse
Affiliation(s)
- Samuel Chao Ming Yeo
- Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore, 119260, Singapore
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40506-0509, USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40506-0509, USA
| | - Meng Huang
- Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore, 119260, Singapore
| | - Liliia Kril
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40506-0509, USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40506-0509, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40506-0509, USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, 40506-0509, USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, 40506-0509, USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0093, USA
| | - Hai-Shu Lin
- Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore, 119260, Singapore.
| |
Collapse
|
39
|
Frasinyuk MS, Bondarenko SP, Sviripa VM, Burikhanov R, Rangnekar VM, Liu C, Watt DS. Development of 6H-Chromeno[3,4- c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues. Tetrahedron Lett 2015; 56:3382-3384. [PMID: 26236052 DOI: 10.1016/j.tetlet.2015.01.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Nitrosation and cyclization of 4-(3-aminothieno[2,3-b]pyridine-2-yl)-2H-chromen-2-ones 1 afforded substituted 6H-chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones 2 that inhibited the intermediary filament protein, vimentin, at low micromolar concentrations. This inhibition promoted the secretion of Prostate Apoptosis Response-4 protein (Par-4), which selectively triggered apoptosis in prostate cancer cells such as CWR22Rv1, LNCaP-derivative C4-2B, PC-3 and its aggressive analog, PC-3 MM2.
Collapse
Affiliation(s)
- Mykhaylo S Frasinyuk
- Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Science of Ukraine, Kyiv 02094, Ukraine
| | | | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States ; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Ravshan Burikhanov
- Department of Radiation Medicine, College of Medicine; University of Kentucky, Lexington, KY 40536-0096, United States
| | - Vivek M Rangnekar
- Department of Radiation Medicine, College of Medicine; University of Kentucky, Lexington, KY 40536-0096, United States ; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States ; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States ; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States ; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States
| |
Collapse
|
40
|
Frasinyuk MS, Bondarenko SP, Khilya VP, Liu C, Watt DS, Sviripa VM. Synthesis and tautomerization of hydroxylated isoflavones bearing heterocyclic hemi-aminals. Org Biomol Chem 2015; 13:1053-67. [PMID: 25412895 PMCID: PMC5571763 DOI: 10.1039/c4ob02137a] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The aminomethylation of hydroxylated isoflavones with 2-aminoethanol, 3-amino-1-propanol, 4-amino-1-butanol, and 5-amino-1-pentanol in the presence of excess formaldehyde led principally to 9-(2-hydroalkyl)-9,10-dihydro-4H,8H-chromeno[8,7-e][1,3]-oxazin-4-ones 4 and/or the tautomeric 7-hydroxy-8-(1,3-oxazepan-3-ylmethyl)-4H-chromen-4-ones 5. The ratio of these tautomers was dependent on solvent polarity, electronic effects of aryl substituents in the isoflavone and the structure of the amino alcohol. NMR studies confirmed the interconversion of tautomeric forms.
Collapse
Affiliation(s)
- Mykhaylo S Frasinyuk
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA.
| | | | | | | | | | | |
Collapse
|
41
|
Matveev SV, Kwiatkowski S, Sviripa VM, Fazio RC, Watt DS, LeVine H. Tritium-labeled (E,E)-2,5-bis(4'-hydroxy-3'-carboxystyryl)benzene as a probe for β-amyloid fibrils. Bioorg Med Chem Lett 2014; 24:5534-6. [PMID: 25452000 PMCID: PMC4254541 DOI: 10.1016/j.bmcl.2014.09.075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 09/11/2014] [Accepted: 09/24/2014] [Indexed: 12/20/2022]
Abstract
Accumulation of Aβ in the brains of Alzheimer disease (AD) patients reflects an imbalance between Aβ production and clearance from their brains. Alternative cleavage of amyloid precursor protein (APP) by processing proteases generates soluble APP fragments including the neurotoxic amyloid Aβ40 and Aβ42 peptides that assemble into fibrils and form plaques. Plaque-buildup occurs over an extended time-frame, and the early detection and modulation of plaque formation are areas of active research. Radiolabeled probes for the detection of amyloid plaques and fibrils in living subjects are important for noninvasive evaluation of AD diagnosis, progression, and differentiation of AD from other neurodegenerative diseases and age-related cognitive decline. Tritium-labeled (E,E)-1-[(3)H]-2,5-bis(4'-hydroxy-3'-carbomethoxystyryl)benzene possesses an improved level of chemical stability relative to a previously reported radioiodinated analog for radiometric quantification of Aβ plaque and tau pathology in brain tissue and in vitro studies with synthetic Aβ and tau fibrils.
Collapse
Affiliation(s)
- Sergey V Matveev
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536-0230, United States
| | - Stefan Kwiatkowski
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States
| | - Robert C Fazio
- ViTrax Radiochemicals, 660 S. Jefferson Street, Unit E, Placentia, CA 92870, United States
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, United States; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, United States.
| | - Harry LeVine
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536-0230, United States.
| |
Collapse
|
42
|
Hamza A, Wagner JM, Wei NN, Kwiatkowski S, Zhan CG, Watt DS, Korotkov KV. Application of the 4D fingerprint method with a robust scoring function for scaffold-hopping and drug repurposing strategies. J Chem Inf Model 2014; 54:2834-45. [PMID: 25229183 PMCID: PMC4210175 DOI: 10.1021/ci5003872] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
Two
factors contribute to the inefficiency associated with screening
pharmaceutical library collections as a means of identifying new drugs:
[1] the limited success of virtual screening (VS) methods in identifying
new scaffolds; [2] the limited accuracy of computational methods in
predicting off-target effects. We recently introduced a 3D shape-based
similarity algorithm of the SABRE program, which encodes a consensus
molecular shape pattern of a set of active ligands into a 4D fingerprint
descriptor. Here, we report a mathematical model for shape similarity
comparisons and ligand database filtering using this 4D fingerprint
method and benchmarked the scoring function HWK (Hamza–Wei–Korotkov),
using the 81 targets of the DEKOIS database. Subsequently, we applied
our combined 4D fingerprint and HWK scoring function
VS approach in scaffold-hopping and drug repurposing using the National
Cancer Institute (NCI) and Food and Drug Administration (FDA) databases,
and we identified new inhibitors with different scaffolds of MycP1 protease from the mycobacterial ESX-1 secretion system. Experimental
evaluation of nine compounds from the NCI database and three from
the FDA database displayed IC50 values ranging from 70
to 100 μM against MycP1 and possessed high structural
diversity, which provides departure points for further structure–activity
relationship (SAR) optimization. In addition, this study demonstrates
that the combination of our 4D fingerprint algorithm and the HWK scoring function may provide a means for identifying
repurposed drugs for the treatment of infectious diseases and may
be used in the drug-target profile strategy.
Collapse
Affiliation(s)
- Adel Hamza
- Department of Molecular and Cellular Biochemistry, ‡Center for Structural Biology, §Center for Pharmaceutical Research and Innovation, College of Pharmacy, ∥Molecular Modeling and Biopharmaceutical Center, and ⊥Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky 40536, United States
| | | | | | | | | | | | | |
Collapse
|
43
|
Burikhanov R, Sviripa VM, Hebbar N, Zhang W, Layton WJ, Hamza A, Zhan CG, Watt DS, Liu C, Rangnekar VM. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol 2014; 10:924-926. [PMID: 25218743 PMCID: PMC4201913 DOI: 10.1038/nchembio.1631] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 08/13/2014] [Indexed: 12/17/2022]
Abstract
The tumor suppressor protein Par-4, which is secreted by normal cells, selectively induces apoptosis in cancer cells. We identified a 3-arylquinoline derivative, designated Arylquin 1, as a potent Par-4 secretagogue in cell cultures and mice. Mechanistically, Arylquin 1 binds to vimentin, displaces Par-4 from vimentin for secretion and triggers the efficient paracrine apoptosis of diverse cancer cells. Thus, targeting vimentin with Par-4 secretagogues efficiently induces paracrine apoptosis of tumor cells.
Collapse
Affiliation(s)
- Ravshan Burikhanov
- Department of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Nikhil Hebbar
- Graduate Center for Toxicology, College of Medicine, University of Kentucky, Lexington, KY 40536
| | - Wen Zhang
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| | - W John Layton
- Department of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY 40536
| | - Adel Hamza
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - Chang-Guo Zhan
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536.,Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536.,Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky, Lexington, KY 40536
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536.,Department of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY 40536
| | - Chunming Liu
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| | - Vivek M Rangnekar
- Department of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, KY 40536.,Graduate Center for Toxicology, College of Medicine, University of Kentucky, Lexington, KY 40536.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536
| |
Collapse
|
44
|
Sviripa VM, Zhang W, Balia AG, Tsodikov OV, Nickell JR, Gizard F, Yu T, Lee EY, Dwoskin LP, Liu C, Watt DS. 2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2. J Med Chem 2014; 57:6083-91. [PMID: 24950374 PMCID: PMC4111374 DOI: 10.1021/jm5004864] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
![]()
Inhibition
of the catalytic subunit of the heterodimeric methionine
S-adenosyl transferase-2 (MAT2A) with fluorinated N,N-dialkylaminostilbenes (FIDAS agents) offers a
potential avenue for the treatment of liver and colorectal cancers
where upregulation of this enzyme occurs. A study of structure–activity
relationships led to the identification of the most active compounds
as those with (1) either a 2,6-difluorostyryl or 2-chloro-6-fluorostyryl
subunit, (2) either an N-methylamino or N,N-dimethylamino group attached in a para orientation relative to the 2,6-dihalostyryl subunit, and (3) either
an N-methylaniline or a 2-(N,N-dimethylamino)pyridine ring. These modifications led to
FIDAS agents that were active in the low nanomolar range, that formed
water-soluble hydrochloride salts, and that possessed the desired
property of not inhibiting the human hERG potassium ion channel at
concentrations at which the FIDAS agents inhibit MAT2A. The active
FIDAS agents may inhibit cancer cells through alterations of methylation
reactions essential for cancer cell survival and growth.
Collapse
Affiliation(s)
- Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Center for Pharmaceutical Research and Innovation, and ∥Markey Cancer Center, University of Kentucky , Lexington, Kentucky 40506-0509, United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Frasinyuk MS, Kwiatkowski S, Wagner JM, Evans TJ, Reed RW, Korotkov KV, Watt DS. Pentapeptide boronic acid inhibitors of Mycobacterium tuberculosis MycP1 protease. Bioorg Med Chem Lett 2014; 24:3546-8. [PMID: 24915878 DOI: 10.1016/j.bmcl.2014.05.056] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Revised: 05/14/2014] [Accepted: 05/15/2014] [Indexed: 01/16/2023]
Abstract
Mycosin protease-1 (MycP1) cleaves ESX secretion-associated protein B (EspB) that is a virulence factor of Mycobacterium tuberculosis, and accommodates an octapeptide, AVKAASLG, as a short peptide substrate. Because peptidoboronic acids are known inhibitors of serine proteases, the synthesis and binding of a boronic acid analog of the pentapeptide cleavage product, AVKAA, was studied using MycP1 variants from Mycobacterium thermoresistible (MycP1mth), Mycobacterium smegmatis (MycP1msm) and M. tuberculosis (MycP1mtu). We synthesized the boropentapeptide, HAlaValLysAlaAlaB(OH)2 (1) and the analogous pinanediol PD-protected HAlaValLysAlaAlaBO2(PD) (2) using an Fmoc/Boc peptide strategy. The pinanediol boropentapeptide 2 displayed IC50 values 121.6±25.3 μM for MycP1mth, 93.2±37.3 μM for MycP1msm and 37.9±5.2 μM for MycP1mtu. Such relatively strong binding creates a chance for crystalizing the complex with 2 and finding the structure of the unknown MycP1 catalytic site that would potentially facilitate the development of new anti-tuberculosis drugs.
Collapse
Affiliation(s)
- Mykhaylo S Frasinyuk
- Institute of Bioorganic Chemistry and Petrochemistry, Kyiv-94 02660, Ukraine; Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
| | - Stefan Kwiatkowski
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA
| | - Jonathan M Wagner
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
| | - Timothy J Evans
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
| | - Robert W Reed
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
| | - Konstantin V Korotkov
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA
| | - David S Watt
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, USA; Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA; Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA.
| |
Collapse
|
46
|
Hamza A, Wagner JM, Evans TJ, Frasinyuk MS, Kwiatkowski S, Zhan CG, Watt DS, Korotkov KV. Novel mycosin protease MycP₁ inhibitors identified by virtual screening and 4D fingerprints. J Chem Inf Model 2014; 54:1166-73. [PMID: 24628123 PMCID: PMC4010288 DOI: 10.1021/ci500025r] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The rise of drug-resistant Mycobacterium tuberculosis lends urgency to the need for new drugs for the treatment of tuberculosis (TB). The identification of a serine protease, mycosin protease-1 (MycP₁), as the crucial agent in hydrolyzing the virulence factor, ESX-secretion-associated protein B (EspB), potentially opens the door to new tuberculosis treatment options. Using the crystal structure of mycobacterial MycP₁ in the apo form, we performed an iterative ligand- and structure-based virtual screening (VS) strategy to identify novel, nonpeptide, small-molecule inhibitors against MycP₁ protease. Screening of ∼485,000 ligands from databases at the Genomics Research Institute (GRI) at the University of Cincinnati and the National Cancer Institute (NCI) using our VS approach, which integrated a pharmacophore model and consensus molecular shape patterns of active ligands (4D fingerprints), identified 81 putative inhibitors, and in vitro testing subsequently confirmed two of them as active inhibitors. Thereafter, the lead structures of each VS round were used to generate a new 4D fingerprint that enabled virtual rescreening of the chemical libraries. Finally, the iterative process identified a number of diverse scaffolds as lead compounds that were tested and found to have micromolar IC₅₀ values against the MycP₁ target. This study validated the efficiency of the SABRE 4D fingerprints as a means of identifying novel lead compounds in each screening round of the databases. Together, these results underscored the value of using a combination of in silico iterative ligand- and structure-based virtual screening of chemical libraries with experimental validation for the identification of promising structural scaffolds, such as the MycP₁ inhibitors.
Collapse
Affiliation(s)
- Adel Hamza
- Department of Molecular and Cellular Biochemistry, University of Kentucky , Lexington, Kentucky 40536, United States
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Zhang W, Sviripa V, Chen X, Shi J, Yu T, Hamza A, Ward ND, Kril LM, Vander Kooi CW, Zhan CG, Evers BM, Watt DS, Liu C. Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol 2013; 8:796-803. [PMID: 23363077 DOI: 10.1021/cb3005353] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Methionine S-adenosyltransferase 2A (MAT2A) is the catalytic subunit for synthesis of S-adenosylmethionine (SAM), the principal methyl donor in many biological processes. MAT2A is up-regulated in many cancers, including liver cancer and colorectal cancer (CRC) and is a potentially important drug target. We developed a family of fluorinated N,N-dialkylaminostilbene agents, called FIDAS agents, that inhibit the proliferation of CRC cells in vitro and in vivo. Using a biotinylated FIDAS analogue, we identified the catalytic subunit of MAT2A as the direct and exclusive binding target of these FIDAS agents. MAT2B, an associated regulatory subunit of MAT2A, binds indirectly to FIDAS agents through its association with MAT2A. FIDAS agents inhibited MAT2A activity in SAM synthesis, and depletion of MAT2A by shRNAs inhibited CRC cell growth. A novel FIDAS agent delivered orally repressed CRC xenografts in athymic nude mice. These findings suggest that FIDAS analogues targeting MAT2A represent a family of novel and potentially useful agents for cancer treatment.
Collapse
Affiliation(s)
- Wen Zhang
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Vitaliy Sviripa
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Xi Chen
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Jiandang Shi
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Tianxin Yu
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Adel Hamza
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Nicholas D. Ward
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Liliia M. Kril
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Craig W. Vander Kooi
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Chang-Guo Zhan
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - B. Mark Evers
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - David S. Watt
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| | - Chunming Liu
- Department
of Molecular and Cellular Biochemistry, ‡Department of Surgery, College
of Medicine, §Department of Pharmaceutical Sciences, College of Pharmacy, ∥Center for Pharmaceutical
Research and Innovation, and ⊥Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40506-0509,
United States
| |
Collapse
|
48
|
Sviripa V, Zhang W, Conroy MD, Schmidt ES, Liu AX, Truong J, Liu C, Watt DS. Fluorinated N,N'-diarylureas as AMPK activators. Bioorg Med Chem Lett 2013; 23:1600-3. [PMID: 23414799 DOI: 10.1016/j.bmcl.2013.01.096] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Revised: 01/17/2013] [Accepted: 01/22/2013] [Indexed: 01/07/2023]
Abstract
Adenosine monophosphate-activated kinase (AMPK) plays a central role in regulating energy homeostasis in eukaryotic cells. AMPK also regulates lipid synthesis by inhibiting acetyl-CoA carboxylase (ACC) and regulates mTOR signaling by activating TSC2. Due to its important roles in cell metabolism, AMPK is an attractive target for metabolic diseases, such as type II diabetes and obesity. AMPK activators, such as metformin, that are used for diabetes treatment are also effective anticancer agents. However, the efficacies of many known AMPK activators are relatively low. For example, metformin activates AMPK at millimolar levels. In this study, we identified a novel family of AMPK activators, namely fluorinated N,N'-diarylureas, that activate AMPK at 1-3μM concentrations. These novel agents strongly inhibit the proliferation of colon cancer cells. We studied the potential mechanisms of these agents, performed a structure-activity relationship (SAR) study and identified several fluorinated N,N'-diarylureas as potent AMPK activators.
Collapse
Affiliation(s)
- Vitaliy Sviripa
- Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509, United States
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Yeo YS, Nybo SE, Chittiboyina AG, Weerasooriya AD, Wang YH, Góngora-Castillo E, Vaillancourt B, Buell CR, DellaPenna D, Celiz MD, Jones AD, Wurtele ES, Ransom N, Dudareva N, Shaaban KA, Tibrewal N, Chandra S, Smillie T, Khan IA, Coates RM, Watt DS, Chappell J. Functional identification of valerena-1,10-diene synthase, a terpene synthase catalyzing a unique chemical cascade in the biosynthesis of biologically active sesquiterpenes in Valeriana officinalis. J Biol Chem 2012; 288:3163-73. [PMID: 23243312 DOI: 10.1074/jbc.m112.415836] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Valerian is an herbal preparation from the roots of Valeriana officinalis used as an anxiolytic and sedative and in the treatment of insomnia. The biological activities of valerian are attributed to valerenic acid and its putative biosynthetic precursor valerenadiene, sesquiterpenes, found in V. officinalis roots. These sesquiterpenes retain an isobutenyl side chain whose origin has been long recognized as enigmatic because a chemical rationalization for their biosynthesis has not been obvious. Using recently developed metabolomic and transcriptomic resources, we identified seven V. officinalis terpene synthase genes (VoTPSs), two that were functionally characterized as monoterpene synthases and three that preferred farnesyl diphosphate, the substrate for sesquiterpene synthases. The reaction products for two of the sesquiterpene synthases exhibiting root-specific expression were characterized by a combination of GC-MS and NMR in comparison to the terpenes accumulating in planta. VoTPS7 encodes for a synthase that biosynthesizes predominately germacrene C, whereas VoTPS1 catalyzes the conversion of farnesyl diphosphate to valerena-1,10-diene. Using a yeast expression system, specific labeled [(13)C]acetate, and NMR, we investigated the catalytic mechanism for VoTPS1 and provide evidence for the involvement of a caryophyllenyl carbocation, a cyclobutyl intermediate, in the biosynthesis of valerena-1,10-diene. We suggest a similar mechanism for the biosynthesis of several other biologically related isobutenyl-containing sesquiterpenes.
Collapse
Affiliation(s)
- Yun-Soo Yeo
- Plant Biology Program, University of Kentucky, Lexington, Kentucky 40503, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Lin HS, Sviripa VM, Watt DS, Liu C, Xiang TX, Anderson BD, Ong PS, Ho PC. Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: application to a pharmacokinetic study. J Pharm Biomed Anal 2012; 72:115-20. [PMID: 23146234 DOI: 10.1016/j.jpba.2012.09.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2012] [Revised: 09/16/2012] [Accepted: 09/26/2012] [Indexed: 11/24/2022]
Abstract
trans-2,6-Difluoro-4'-N,N-dimethylaminostilbene (DFS), a synthetic stilbene, displayed potent pre-clinical anti-cancer activities exceeding that observed for naturally occurring resveratrol. In this study, a simple and sensitive HPLC method was developed and validated to quantify DFS in rat plasma. The lower limit of quantification (LLOQ) was 5 ng/ml. The intra- and inter-day variation in terms of relative standard deviation (RSD) was all less than 10%. The bias rate ranged from -11.5% to 6.2% while the absolute recovery ranged from 94.1 ± 2.3 to 97.3 ± 4.4%. The pharmacokinetic profiles of DFS were examined in Sprague-Dawley rats after intravenous administration (2 mg/kg). DFS displayed moderate clearance (Cl=61.5 ± 17.7 ml/min/kg) and a relatively prolonged terminal elimination half-life (t(1/2 λz)) of 351 ± 180 min. Aqueous solubility played a crucial role in the oral absorption of DFS. When DFS was given as a suspension (6 mg/kg), the absolute oral bioavailability (F) was almost negligible. However, when DFS was given in a solution prepared with hydroxypropyl-β-cyclodextrin (6 mg/kg), the F was 12.4 ± 10.7%. Dose-escalation to 15 mg/kg resulted in much higher systemic exposure (F=40.2 ± 10.0%). As DFS is orally available after formulation with hydroxypropyl-β-cyclodextrin and pharmacologically active systemic concentrations could be achieved after a single oral dose, the use of DFS as a cancer chemopreventive/chemotherapeutic agent is possible.
Collapse
Affiliation(s)
- Hai-Shu Lin
- Department of Pharmacy, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260, Singapore.
| | | | | | | | | | | | | | | |
Collapse
|